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ABSTRACT 
 
Skin cancer is one of the most common health issues afflicting people in 
many countries, particularly in Australia. The major cause of skin cancer is 
ultraviolet radiation (UV), which is also needed for vitamin D synthesis. There 
is also evidence from the Mason group that the hormonally active form of 
vitamin D, 1α,25-hydroxyvitamin D3 (1,25(OH)2D3), provides photoprotection. 
Vitamin D-related compounds having similar chemo-potential include 
lumisterol, a derivative of an over-irradiation product, which has been shown 
to be photoprotective in short term studies by the Mason group. 
 
In previous studies, it had already been shown that the vitamin D receptor is 
critical to activate vitamin D induced photoprotection. Vitamin D receptor 
knockout mice were susceptible to carcinogenesis upon UV irradiation (Ellison 
et al., 2008). However, it was also noted that knockout of 1α-hydroxylase 
enzyme (CYP27B1), the enzyme essential for the production of 1,25(OH)2D3, 
does not increase susceptibility to photocarcinogenesis (Bikle, 2008). This led 
to the suggestion that other vitamin D compounds such as 20-hydroxyvitamin 
D3 (20(OH)D3) that are naturally made in irradiated skin without 1α- 
hydroxylation, through the action of the enzyme CYP11A1 on vitamin D itself 
could deliver photoprotective effects (Slominski et al., 2010). 
 
Studies on the effects of 20(OH)D3 on DNA damage and immunosuppression 
done in our laboratory by colleagues, revealed that 20(OH)D3 is as effective 
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as 1,25(OH)2D3 in reducing thymine dimer formation and UVR-induced 
immunosuppression in female hairless Skh:hr1 mice (Tongkao-on et al., 
2015). 
 
The aim of this project was to explore whether 20-hydroxyvitamin D3 
(20(OH)D3), a product of vitamin D3 hydroxylation, provides protection against 
UV-induced photocarcinogenesis. In order to investigate whether the 
protection against acute UV-induced damage translates into prevention of 
skin carcinogenesis, the major, in vivo component of this study involved a 40 
week photocarcinogenesis study and contact hypersensitivity (CHS) response 
experiment, with 1,25(OH)2D3 and 20(OH)D3 applied as topical treatments 
post UV irradiation. The results from the in vivo study showed that 
1,25(OH)2D3 was effective at inhibiting UV-induced tumour formation and 
progression, but 20(OH)D3 was not observed to be effective in reducing the 
following parameters: tumour incidence, tumour latency, tumour multiplicity 
and squamous cell carcinoma (SCC) incidence. 
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1 INTRODUCTION 
1.1 SKIN ANATOMY AND PHYSIOLOGY 
The skin forms the outermost layer of the human body and serves as the organ of 
first line of defence, protecting the internal tissue organs from external sources of 
damage such as UV irradiation, chemical, bacterial and viral infections. Other than its 
protective effects, skin is also involved in important functions such as 
thermoregulation, sensory perception, control of fluid loss and vitamin D synthesis. 
 
The skin is also known as the integument and consists of two layers; the epidermis 
and the underlying dermis. Beneath the dermis is a subcutaneous tissue known as 
hypodermis, which is theoretically not considered to be part of the skin. 
 
1.1.1 EPIDERMIS 
 
Figure 1.1 Layers of epidermis (McLafferty et al., 2012) 
The epidermis is the outermost layer of the skin. It is continuously renewing, 
stratified, squamous epithelium that is further subdivided into five layers; stratum 
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corneum, stratum lucidum, stratum granulosum, stratum spinosum and stratum 
basale. These layers of epidermis consist of four different cell types that are 
interdependent functional units. Each cell relies upon the modulation and regulation 
of surrounding tissue cells. The cells are called keratinocytes, melanocytes, 
Langerhans’ cells and Merkel cells. Each layer of epidermis has a different 
composition of these cells, reflecting their different structure and roles.  
 
The deepest layer, stratum basale, consists of single row of columnar keratinocytes 
that are capable of dividing as well as melanocytes. Stratum spinosum is the cell 
layer having rounder and ‘spikier’ appearance, where the keratinocytes are tightly 
held by desmosomes, contributing to the tensile strength and flexibility of the skin. 
This layer also contains Langerhans’ cells, specialised dendritic cells of the immune 
system that are important in immune surveillance. Stratum granulosum consists of 
three to five layers of flattened keratinocytes that undergo apoptosis in this layer. 
These keratinocytes lose nuclei in this layer are left mostly with keratin. Stratum 
lucidum contains three to five layers of clear, dead keratinocytes, and is found only in 
areas where the skin is thick. Stratum corneum is the uppermost layer of the 
epidermis and consist of 25-30 layers of flattened, dead keratinocytes (McLafferty et 
al., 2012). 
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1.1.1.1 KERATINOCYTES 
 
Figure 1.2 Keratinisation in the epidermis. (Eckert, 1989) 
 
Keratinocytes are the most abundant type of cells in the epidermis, constituting about 
80% of total population of cells. A keratinocyte is characterised by keratin filaments; 
proteins that serve a structural role.  
 
Keratinocytes are spread over the five layers of epidermis, with each layer reflecting 
the state of differentiation and the synthetic properties of keratinocytes. The 
differentiation is also known as keratinisation, a process consisting of morphologic 
and metabolic changes in keratinocytes that occurs progressively as they move up 
the layers. Initially, keratinocytes arise at the basal layer of the epidermis and as they 
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migrate to the spinous layer, their shapes become more flattened and abundant of 
desmosomes, which promote cell-to-cell adhesion, thereby providing resistance to 
mechanical stress. Eventually, keratinocytes terminally differentiate to form a 
cornified layer, a dead surface layer of the skin (Figure 1.1). 
 
During this process, the keratinocyte undergoes some major changes, including an 
increase in cell size, structural reorganization, eventual loss of organelles from the 
cell, dehydration and the synthesis of important structural and catalytic proteins. 
Some of important proteins synthesised include involucrin, the keratins, filaggrin, and 
transglutaminase, all of which are involved in maintaining integrity and cornification of 
the epidermis (Eckert and Rorke, 1989). 
 
Mitotically active keratinocyte stem cells primarily reside in the stratum basale layer. 
These stem cells are clonogenic cells, cells that have a long life span and are able to 
undergo divisions while moving up towards the epidermal surface, where they are 
terminally differentiated (Haake and Holbrook, 1999). 
 
1.1.1.2 MELANOCYTES 
Melanocytes are dendritic cells responsible for pigmentation of the skin. They are 
derived from the neural crest, and reside mostly in the stratum basale. Melanocytes 
are characterised by a special organelle called melanosome, which synthesises 
melanin, a pigment responsible for colouring of the skin. Each melanocyte is thought 
to coexist with 36 basal and suprabasal keratinocytes, forming an ‘epidermal melanin 
unit’. In this unit, melanocytes and keratinocytes interact with each other for 
functional and structural roles. The anatomical relationship of an epidermal melanin 
unit is important for melanogenesis.  
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Melanogenesis or cutaneous pigmentation, is a two step process. First of all, 
melanosomes within a melanocyte produce a pigment, melanin. Then, through the 
dendritic interaction by melanocytes with keratinocytes, melanin is transferred into 
the keratinocyte. The melanin covers over the nuclei of keratinocyte, acting efficiently 
as a protection against DNA damage. The distribution of melanin in the upper layers 
of the epidermis play a significant role in determining its photoprotective value to 
underlying cells. Lower layer of epidermis contains not only melanocytes but also 
keratinocyte stem cells, which are highly proliferative and are not lost via 
desquamation and thus are able to give rise to various types of skin cancers. 
However, with the melanin protecting the cells in the upper layer of epidermis from 
UVR, UVR-induced DNA damage in the lower layer of epidermis is prevented 
(Yamaguchi et al., 2006). 
 
1.1.1.3 LANGERHANS CELLS 
Langerhans cells have an immunosurveillance ability and mainly reside in the 
suprabasal epidermal layers but also in the spinous and granular layers of the skin. 
However, Langerhans cells are not exclusive to the skin but are also found in the 
other parts of the body such as oral cavity and the oesophagus (Haake and 
Holbrook, 1999). 
 
As part of immune surveillance, Langerhans cells are antigen-presenting cells and 
thus are able to ingest antigens and present them for T cell stimulation. They are 
dendritic cells that do not form junctions with the neighbouring cells. Langerhans 
cells thus serve important functions and are necessary for the defence against 
diseases and UV radiation (Haake and Holbrook, 1999). Also, recent studies have 
found that resting Langerhans cells induce the proliferation of the skin resident 
regulatory T cell, cells that are thought to regulate inflammation in peripheral tissue 
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and possibly suppress cytokine production of effector T cells, though the role is 
incompletely characterised (Seneschal et al., 2012). 
 
1.1.1.4 MERKEL CELLS 
Similar to melanocytes, Merkel cells are primarily found in the stratum basale 
scattered among the keratinocytes. Merkel cells serve as mechanoreceptors with 
flattened process of sensory neuron called a Merkel disc, and process touch signals 
upon application of a tactile stimulus. When keratinocytes are deformed, they send 
signals to the Merkel cells and as a result chemical transmitters are released from 
the Merkel cells (Haake and Holbrook, 1999; McLafferty et al., 2012). 
 
1.1.1.5 !" T CELLS 
Human skin contains large number of !"  T cells, which are memory T cells 
consisting of both CD4+ and CD8+ subsets. Of CD4+ subset, about 10-20% of T 
cells express Foxp3, a marker indicative of regulatory T cell phenotype (Treg). These 
regulatory T cells produced more of interleukin 17 (IL-17) in psoriatic skin than in 
normal skin, and also upon exposure to UVR.  The role of this population of cells has 
been highlighted in protection against cell injury, as IL-17 is known to induce 
molecules involved in cell apoptosis and growth arrest, processes that are important 
in DNA repair response (Heath et al., 2013; MacLeod et al., 2014). 
 
1.1.1.6 OTHER CELLS 
Recent evidence suggests important immunostimulatory role of dermal dendritic cells 
(DDCs) that are thought to arise from bone marrow HSC-derived lineage. They 
induce IL-10 secreting regulatory T cells and T cell hyperresponsiveness to antigenic 
stimulation. Cytokines such as IL-10 secreted by T-regs is known to suppress cellular 
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immune reactions such as contact hypersensitivity reactions (CHS). This suggests 
that DDCs and regulatory T cells have role in suppressing skin inflammation (Haniffa 
et al., 2015). 
 
In addition, studies have found skin-invading immune cells known as !" T cells that 
may drive skin inflammation. The fact that this unconventional lymphocyte 
population, rather than the TH17 subset, is the primary source of IL-17 in psoriatic 
patient suggests its potential role in cellular immune reactions upon exposure to UVR 
(Becher and Pantelyushin., 2012). Also, the role of !"  T cells in epidermal 
homeostasis and tissue repair have been highlighted as they seem to produce 
growth factors such as fibroblast growth factor (FGF7), FGF9 and insulin-like growth 
factor, which all promote the survival of keratinocytes (Heath et al., 2013; MacLeod 
et al., 2014; Pasparakis et al., 2014). 
 
 
1.1.2 DERMIS 
 
Figure 1.3 Layers of the skin. (McLafferty, 2012) 
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The dermis is the layer beneath the epidermis, which is further subdivided into two 
layers; reticular and papillary layers. The reticular layer contains the fibroelastic 
tissue, network of collagen, elastic fibres and the extracellular matrix, providing 
physical support for the epidermis. The papillary layer contains the blood vessels to 
provide nutrients for the epidermis, lymph vessels, nerve endings, glands and hair 
follicles (McLafferty et al., 2012). 
 
1.1.2.1 FIBROBLASTS 
Fibroblasts are the most abundant type of cells in the dermis. They are the cells that 
produce various different types of collagen. Synthesis of collagen and other 
components of the extracellular matrix are especially important in healing of the skin. 
Dermal fibroblasts also synthesise other components of the extracellular matrix such 
as elastin, proteoglycans and fibronectin (Rittie, 2005).  
 
1.1.3 HYPODERMIS 
The hypodermis is composed mostly of adipocytes. It is technically called a 
subcutaneous tissue in which fatty cells serve as energy reservoir and a mechanical 
shock absorber. Its thickness varies along different parts of human body (Haake and 
and Holbrook, 1999). 
 
 9 
1.1.4 COMPARISON OF SKIN IN MICE AND HUMANS 
 
 
Figure 1.4 Skin in mice and humans (Pasparakis et al., 2014) 
 
Structures and cellular components of the skin in mice and humans are largely 
similar. Like human skin, mouse skin also consists of the epidermis, dermis and 
hypodermis. Main differences between two species are that human skin has a thicker 
epidermis and dermis than mice skin, and a population of Vγ5+ dendritic epidermal T 
cells (DETCs) that are prominent in mice skin are absent in human skin. These 
differences should be taken into account when interpreting the cellular inflammation 
studies in mouse models in relation to mechanisms that drive inflammation in human 
skin (Pasparakis et al., 2014). 
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1.2 ULTRAVIOLET RADIATION (UVR) 
Human skin is constantly under risk of DNA damage due to various environmental 
factors, of which UVR is known to be the most potent environmental factor to cause 
skin tumours (Brenner and Hearing, 2008). 
 
1.2.1 ENERGY FROM UVR 
UVR reaching the earth consists of three types, long wavelength UVA (315 to 400 
nm), short wavelength UVB (290 to 315 nm) and UVC (100 to 290 nm) radiation 
(Figure 1.3). UVR that reaches the surface of the earth is mostly UVA and a small 
percentage (approximately 5%) UVB, whilst UVC is filtered out by atmospheric 
oxygen and the ozone layer. Thus, human skin is mostly exposed to wavelengths 
UVA and UVB. UVB is known to induce DNA damage directly because human DNA 
absorbs UVR maximally in the range of 245 to 290 nm. On the other hand, UVA 
induces indirect DNA damages by producing reactive oxygen species (ROS). 
(McGregor, 1999).  
 
 
Figure 1.5 UVR spectrum. (Matsumura and Ananthaswamy, 2004) 
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1.2.2 CUTANEOUS PATHOLOGICAL EFFECTS 
In general, UVR is responsible for various pathological effects of the skin. Some of 
the acute effects may include photodamage, erythema, mutation and 
immunosuppression. UVR can also induce chronic effects such as 
photocarcinogenesis (Brenner and Hearing, 2008). 
 
1.2.3 GENERAL BIOLOGICAL EFFECTS OF UVR 
As UVC is blocked by the Earth’s stratospheric ozone layer, it is mainly UVA and 
UVB that have significant biological consequences on human skin and eyes. 
Although UVA is the more predominant type of solar UV radiation than UVB, it is 
known to be less carcinogenic than UVB, and is mainly responsible for aging and 
wrinkling of the skin (Matusumura and Ananthaswamy, 2004). However, there are 
some studies that suggest that UVA may have an important role in cutaneous 
melanoma (Moan et al., 2014). The effects of UVB from the sunlight are profound in 
that upon absorption into the skin, UVB is known to cause sunburn inflammation 
(erythema), oedema, skin pigmentation, photoaging, immunosuppression and skin 
cancer (Kochevar et al, 1999.; Mcgregor and Hawk 1999; Pathak et al, 1999). The 
extent of damage done by UVB is dependent on the depth of UVB penetration in the 
skin layers (Figure 1.4). 
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Figure 1.6 UVR penetration through the skin. (Kochevar et al. 1999) 
 
As is seen from the Figure 1.4, radiation with shorter wavelengths travels less deeply 
than that with longer wavelengths. For this reason, UVA and UVB penetrate mainly 
the epidermal and the dermal layers of the skin, causing most damage in those 
areas. 
 
Although it is widely known that UVB delivers immunosuppressive effects, the 
potency of UVA on immune suppression has remained somewhat questionable as 
seen in various findings. This difference may be due to differences in subjects 
studied, differences in the irradiation sources, and especially the difference in the 
dosage and time points of irradiation (Kuchel et al, 2002). Firstly, a study from Poon 
et al showed that UVB and UVA induced immune suppression in a dose- and time- 
dependent manner in human subjects. It was found that UVB caused immune 
suppression within 24 hours, whilst UVA required 48 hours to induce suppression. 
Moreover, an interaction of the two caused immune suppression after 72 hours 
(Poon et al, 2005). Also, the results in Reeve et al suggested that an interaction 
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between UVA and UVB bands is more complex in terms of immunological function. 
Their results demonstrated that UVA exposure delivers photoprotective effects 
against UVB induced immune suppression in hairless mice. It was suggested in the 
study that UVA exposure possibly induce the formation of unidentified, yet possibly 
immunoprotective photoproducts (Reeve et al, 1998). In contrast, another study 
revealed that UVA does not induce a significant degree of immune suppression as 
with UVB in human subjects, but only augments solar-simulated ultraviolet-radiation 
induced immunosuppression (Kuchel et al, 2002).  
 
 
1.2.4 ERYTHEMA 
Erythema, or sunburn inflammation, is the body’s initial response to UVR with signs 
of redness, warmth, pain and swelling. These signs seem to be biphasic in animals in 
response to UVB exposure, meaning that they could appear immediately after 
exposure or be delayed for minutes to hours. However, with UVA exposure, 
immediate erythema seems to appear more regularly.  
 
The degree of erythema is largely dependent on the amount of exposure to UVR, but 
also on the types of UV sources, age, skin pigmentation, skin thickness and other 
environmental factors. Exposure to UVR is commonly expressed in terms of minimal 
erythemal dose (MED), the lowest radiation exposure to UVR sufficient to produce 
just perceptible erythema (JPE) on exposed skin after 24 hours. Although the onset 
of erythema in response to UVB and UVA is different, the intensity of erythema is 
higher in both cases following the exposure to multiple MEDs (McGregor, 1999). 
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1.2.5 UVR-INDUCED DNA DAMAGE 
The types of UVR-induced DNA damage can be chiefly categorised into two types: 
DNA lesions caused by absorption of UVR by DNA and oxidative damage via 
formation of reactive oxygen species (ROS). The latter may be less important in 
mutagenesis and carcinogenesis. 
 
1.2.6 DNA LESIONS 
UVR is considered to be more detrimental when it induces DNA damage to the lower 
epidermal layers of skin than the upper layers. This is because the keratinocyte stem 
cells that reside in the lower layers are proliferative and are able to give rise to 
different types of skin cancers (Yamaguchi et al., 2006).  
 
UVR-induced DNA lesions can occur due to the absorption of the UVR by DNA and 
hence the extent and the type of DNA damage are dependent upon the wavelength 
of the incident photons that strike the cells (Douki et al., 2003). The major type of 
DNA photolesion induced by the UVR, cyclobutane pyrimidine dimers (CPDs), 
occurs in adjacent pyrimidines (thymine and/or cytosine), resulting in the formation of 
dimers. Upon DNA absorption of UVB photons, the cyclobutane pyrimidine dimers, 
as shown in Figure 1.5a, are formed. These are dimers between the C-4 and C-5 
carbon atoms of any two adjacent pyrimidine dimers, but mostly between thymine-
thymine dimers (T<>T), with thymine-cytosine (C<>T or T<>C) and cytosine-cytosine 
(C<>C) occurring to a lesser extent (Matsumura and Ananthaswamy, 2002b; Cooke 
et al., 2003).  
 
Although it is known that UVA is poorly absorbed by DNA, UVA may also contribute 
to the formation of CPDs. UVA-induced CPD formation occurs via photosensitisation 
that induces oxidative damage either by charge transfer from excited endogenous 
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chromophores, or by reactions with reactive oxygen species (ROS) that are 
generated at UVA wavelengths (Perdiz et al., 2000). On top of that, it has recently 
been discovered that UVA has a role in inducing cyclobutane pyrimidine dimers in 
melanocytes. A new mechanism was suggested that the cyclobutane pyrimidine 
dimers are generated at least 3 hours after UVA exposure in murine melanocytes, at 
which point generation was offset by DNA repair. This implicated that the 
cyclobutane pyrimidine dimers continue to be generated in melanocytes long after 
UV exposure ends. This delayed production of CPDs in melanocytes was coined as 
“dark CPDs” (Premi et al., 2015). 
 
The second type of photolesion caused frequently by UVR is the 6-4 photoproduct 
[(6-4)PP]. As shown in Figure 1.5b, (6-4)PPs are formed between the 5′ C-4 position 
and the 3′C-6 position of two adjacent pyrimidines, most frequently between thymine-
cytosine (T<>C) and cytosine-cytosine (C<>C) residues (Matsumura and 
Ananthaswamy 2002b). The ratio of (6-4)PP formation is about 20-30 per cent that of 
CPDs, but this ratio appears to be dependent on the DNA sequence and on the 
chromatin environment (Tornaletti and Pfeifer, 1996). Both CPDs and (6-4)PPs affect 
the torsional flexibility of the DNA double helix at the site of damage, causing 
distortions and ultimately affecting the base-pairing ability. These in turn impede the 
key cellular processes such as transcription and replication, thereby inducing 
reduction of RNA synthesis, cell cycle arrest, and cell apoptosis (Tornaletti and 
Pfeifer., 1996; Schul et al., 2002). If not repaired before DNA replication, UVR-
induced DNA lesions can lead to mutations in the DNA sequences. These mutations 
are in the form of C to T and CC to TT transitions, known as UV “signature” 
mutations (Matsumura and Ananthaswamy, 2002b).  
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Figure 1.7 a. Molecular structures of CPD and b. (6-4) photoproduct. 
(Matsumura and Ananthaswamy, 2002b) 
 
The signature mutations are caused by noninstructional insertion of adenine (A) 
nucleotide opposite the UV lesion in the newly synthesised DNA strand by DNA 
polymerase, a mechanism known as the ‘A rule’. This results in the mispairing of 
cytosine with adenine residues, causing delay in the SOS repair of lesions whilst 
facilitating a spontaneous deamination of cytosine in CPDs. UVR-induced 
mutagenesis then occurs in the subsequent round of DNA replication including the 
strands with base-pair changes. This is the case in CC cyclobutane dimers, where a 
CC to TT transition occurs, as two A residues, rather than guanine (G) residues, are 
placed by default opposite the lesion, resulting in mutagenesis. On the other hand, in 
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more common TT cyclobutane pyrimidine dimers, noninstructional insertion of 
adenine would not cause mutation as adenine residue is normally paired with 
thymine residues. Similar mutagenesis could also occur in (6-4)PPs. In (6-4)PPs 
between a pyrimidine and a C residue, the 5’ residue base-pairs correctly but the 3’ 
residue resembles a non-instructional site, meaning that a C to T transition occurs as 
an A residue is inserted opposite the C residue by default (Tessman et al., 1992; 
Matsumura and Ananthaswamy, 2004). 
 
Therefore, UVR-induced mutagenesis can occur via both types of DNA lesions, 
CPDs and (6-4)PPs. Mutagenesis is detrimental to a cell as it disrupts controlled cell 
growth and proliferation, which may eventually lead to cancer formation. It is believed 
that the CPDs are the principal mutagenic lesions in mammalian cells, though (6-
4)PPs are also mutagenic. Part of the reason for this is the fact that the repair of (6-
4)PPs is generally far more rapid than that of CPDs (Mouret et al., 2006). 
 
1.2.6.1 OXIDATIVE DNA DAMAGE 
It was previously noted that UVR could directly cause DNA mutations by inducing the 
formation of CPDs and (6-4) photoproducts. On top of that, UVR can also cause 
DNA mutations indirectly via the formation of reactive oxygen species (ROS), These 
include the superoxide anion (
€ 
O2•− ), hydroxyl radicals (HO·), singlet oxygen (1!!), 
and hydrogen peroxide (H2O2). Reactive oxygen species are normal byproducts of 
cellular metabolism, though they become mutagenic and are the potential initiators 
and promoters of carcinogenesis when produced in excessive amounts (Zhang et al., 
1997). Typical targets of UVR-induced ROS include proteins, lipids and DNA. Of 
these, the guanine base of DNA seems to be a particular target of significance. ROS 
cause several types of DNA damage including strand breaks, modifications of 
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pyrimidine bases and DNA-protein cross-links (Hattori et al., 1996; Klaunig et al., 
2010).  
 
An appropriate biomarker for oxidative DNA damage both in vitro and in vivo is the 
oxidatively modified DNA base product 8-oxo-7,8-dihydro-2’-deoxyguanosine (8-
oxodGuo) otherwise known as 8-hydroxy-2'-deoxyguanosine (8-OHdG). Out of 
reactive oxygen species, hydroxyl radicals seem to be the major culprit of formation 
of 8-OHdG, though singlet oxygen and photodynamic action also play a role. The 
mechanism by which HO· induces the formation is that it initially attacks the DNA 
strand, specifically the nucleobase guanine, forming a radical adduct and then 
through subsequent electron abstraction to form 8-OHdG (Zhang et al., 1997; 
Valavanidis et al., 2009). This oxidation product has been suggested to play a role in 
UVR-induced skin carcinogenesis and the suggestion is further supported by the fact 
that mutagens and carcinogens other than UVR, such as reducing agents and metals 
also modify guanine residues in DNA at the C-8 position (Kasai and Nishimura, 
1984).  
 
Although both UVA and UVB can cause oxidative damage, UVA is generally more 
associated with indirect oxidative damage whilst UVB is regarded to be primarily 
responsible for direct DNA damage via pyrimidine dimer formation (Halliday, 2005). 
Yet, the proportion of UVA and UVB contributing to oxidative damage remains 
controversial as it was found that upon repeated exposure to UVB, there is an 
increase in 8-OHdG in the epidermis of hairless mice (Hattori et al., 1996). 
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1.2.7 DNA REPAIR 
Cells are equipped with special DNA repair machinery in order to counteract DNA-
damaging compounds. Depending on the type of DNA damage, different repair 
systems are activated, including single or double stranded break repair, base 
excision repair, mismatch repair and nucleotide excision repair (NER). Despite 
various types of DNA damage being identified, it is known that more than 99% of 
UVR-induced DNA damage consists of chemical base modifications, with CPDs and 
(6-4)PPs being the most common types of photolesion (Schul et al., 2002). 
 
Nuclear excision repair (NER) is a complex process involving more than 30 gene 
products in which the following five steps are identified (Aboussekhra et al., 1995): 
(1) recognition of a DNA lesion; (2) single strand incision at both sides flanking the 
lesion; (3) excision of a single stranded DNA nucleotide (possibly 24_/32 bases); (4) 
DNA repair synthesis to replace the excised DNA lesion; and (5) ligation of remaining 
single stranded nick (Ichihashi et al., 2003). 
 
In the NER process, xeroderma pigmentosum (XP) factors are the best characterised 
components. These factors are proteins that are required for the initial steps of 
excision repair process, which correct the DNA deficiency of the seven 
complementation groups of XP cells, XP-A to XP-G. For instance, XPA is a DNA 
damage-binding protein and XPC is a single-stranded DNA-binding protein (Naegeli 
and Sugasawa., 2011). 
 
 
UVR-induced DNA damage such as cyclobutane pyrimidine dimers and (6-4)PPs are 
normally repaired by the nucleotide excision repair (NER) pathway. NER is divided 
into two subpathways known as transcription-coupled repair (TCR) and global 
genomic repair (GGR). TCR is responsible for the repair of genes that are being 
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actively transcribed, whereas the GGR pathway is a relatively slower repair pathway 
and is mainly responsible for transcriptionally inactive parts of the genome 
(Berneburg, 2000). The two pathways differ only in the initial step. Mechanisms 
underlying the transcription-coupled repair pathway are not clear yet, but it requires 
the Cockayne syndrome (CS) A and B proteins (CSA and CSB) in the initial damage 
recognition. The subsequent steps for both pathways are identical and explained 
below and illustrated in figure 1.6. 
 
a) Initially in damage recognition step, GGR begins with XPC gene first forming a 
complex with hHR23B, a human RAD23 homolog, and then binds to DNA 
lesion in the genome. In transcription coupled repair, however, a stalled RNA 
polymerase II along with CSA and CSB proteins serve as damage recognition 
signal. 
b) In DNA unwinding step, the lesions are opened by the concerted action of XPA, 
replication protein A (RPA), and the bi-directional XPB/XPD helicase subunits 
of the transcription factor IIH (TFIIH) complex.  
c) During incision of the damaged DNA, the exchange repair cross 
complementing (ERCC1)/XPF complex cuts at the single-strand to double-
strand transition on the 5’ side of the damage, and XPG cuts at the 3′ side of 
the open complex.  
d) Finally, DNA excision and synthesis is accomplished by mammalian DNA 
replication factors such as the heterotrimeric replication protein A (RPA), 
replication factor C (RF-C), proliferating cell nuclear antigen (PCNA), and DNA 
polymerase δ and ε (Matsumura and Ananthaswamy 2002b; Ichihashi et al., 
2003). 
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Figure 1.8 Proposed model for nuclear excision repair subpathways: 
NER consist of two subpathways, global genomic repair (GGR) and 
transcription-coupled repair (TCR). (Matsumura and Anathaswamy, 
2002b) 
 
Defects in both subpathways could lead to three distinct diseases: xeroderma 
pigmentosum (XP), the Cockayne syndrome (CS) and trichothiodystrophy (TTD). Of 
these, only XP patients have a predisposition to skin cancer and photosensitivity 
(Matsumura and Anathaswamy, 2002b). 
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1.2.8 p53 
Since its discovery in 1979 as a cellular Simian virus 40 large T antigen-binding 
protein, p53 has been proposed as the ‘master regulator’ of diverse cellular 
processes including cancer formation (Farnebo et al., 2010). Undoubtedly, p53 is 
one of the most frequently mutated genes in skin carcinogenesis (Nataraj et al., 
1995; Decraene et al., 2001). The human p53 gene encodes a 53-kDa weight protein 
containing 393 amino acids, which is involved in the regulation of the cell cycle and 
facilitation of DNA repair (Harlow et al., 1985; Farnebo et al., 2010). A sequence-
specific DNA binding domain is located within the central, conserved portion of the 
protein and encompasses amino acids 102-292, a region where the majority of 
missense mutations have been detected in tumours of cancer patients (Hollstein et 
al., 1991). As shown in Figure 1.7, p53 responds to many different cellular stressors 
including UV, and subsequently interacts with other genes including the proto-
oncogene MDM2, cyclin-dependent kinase inhibitor WAF1/CIP1/p21 gene product, 
DNA damage inducible GADD45, and BAX and BCL2 to induce cellular processes 
such as cell cycle arrest, DNA repair and apoptosis.  
 
The importance of the p53 gene in DNA repair was noted in earlier studies in which 
the removal of photoproducts in human cells by nuclear excision repair (NER) was 
demonstrated to be regulated by the p53 gene (Ford and Hanawalt, 1997). This 
occurs as UVR-induced photodamage induces an elevation of p53 expression in the 
skin, blocking the cell cycle at G1-S phase, and thereby allowing the repair of the 
damage and/or induction of apoptosis to eliminate cells containing severely damaged 
DNA (Ziegler et al., 1994; Ouhtit et al., 2000). The Mason group has reported a clear 
increase in nuclear p53 protein expression, observed 3 hours post UVB irradiation in 
irradiated keratinocytes treated for 24 hours with 1,25(OH)2D3, thereby highlighting 
the role of p53 in photoprotection by 1,25(OH)2D3 (Gupta Dixon et al., 2007). This 
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p53 accumulation and activation are believed to be triggered by DNA lesions, and 
are mediated through protein phosphorylations and acetylations.  
 
At least 20 sites in the human p53 protein are modified in response to the activation 
of different stress signalling pathways (Saito et al., 2003). UVR leads to 
phosphorylation of p53 at multiple serine residues, including Ser15, Ser20, Ser33, 
Ser37, Ser46 and Ser392 (Ouhtit et al., 2000; Matsumura and Anathaswamy, 2004; 
Melnikova and Anathaswamy, 2005). Phosphorylation of p53 at various N-terminal 
serine residues, including Ser15, Ser20 and Ser37, has been reported to stabilize 
p53, whilst phosphorylation at the C-terminal residues Ser315 and Ser392 has been 
suggested to regulate the oligomerization state of p53 and its ability to bind DNA in a 
sequence-specific manner. Acetylation of lysine residues including Lys370, Lys372, 
Lys373, Lys381, and Lys382 within the C-terminal regulatory domain has been found 
to enhance sequence-specific DNA binding and play a critical role in Mdm2- 
mediated ubiquitination and subsequent degradation (Luo et al., 2003; Saito et al., 
2003). 
 
In normal conditions, p53 is a short-lived nuclear protein with a half-life of ~5–20 min 
in most cell types studied (Giaccia and Kastan, 1998). Under normal cellular 
conditions, p53 is bound to Mdm-2 protein, a 491-amino-acid phosphoprotein that is 
reported to be important in controlling the response of p53 to stress, whereby a 
phosphorylation of Mdm-2 or p53 itself by stress-activated protein kinases could 
prevent their interaction and hence allow the accumulation of p53 (Mayo et al., 
1997). The Mdm-2 gene is a proto-oncogene, whose product promotes the rapid 
degradation of a phosphorylated form of p53 via ubiquitin proteosome pathway 
(Steele et al., 1998; Matsumura and Ananthaswamy, 2002a). 
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Figure 1.9 The cellular response of p53 tumour suppressor gene. 
(Matsumura and Ananthaswamy, 2002a) 
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1.2.9 UVR-INDUCED IMMUNOSUPPRESSION 
UVR in the sunlight not only causes DNA damage but is also known to suppress the 
immune system (Kripke, 1974; Kripke and Fisher, 1976). The UVR-induced 
immunosuppression makes the cell more susceptible to skin carcinogenesis by 
depressing cell mediated immune reactions that normally destroy the developing skin 
tumours (Nghiem et al., 2002). 
 
The immune system in the skin consists of various cell types both in the epidermis 
and dermis, and the cells circulating in the blood and lymphatic system. The main 
cells involved in the skin’s immune system include antigen-presenting Langerhans 
cells in the epidermis, T cells and the keratinocytes. In normal skin, Langerhans cells 
in the epidermis form a dendritic cell network that functions to capture invading 
microorganisms, internalise them, and then process their antigens into a form that 
could be recognized by T cells. They then migrate to the skin-draining lymph nodes 
where they present antigens to naïve T cells to initiate a protective immune response 
(Kripke et al., 1990). However, with UV exposure, the number, migration, antigen-
presenting abilities, other functions and morphology of Langerhans cells are altered, 
resulting in reduced immunosurveillance capability of the skin (Wang et al., 2009). It 
has also been noted that following UVR, the capacity to present antigens on surface 
and the number of Langerhans cells decrease (McGregor, 1999). The role of 
Langerhans cell in UVR-induced immunosuppression is significant in that it was 
found to be essential for both the suppression of contact hypersensitivity (CHS) and 
the induction of regulatory T cells (Schwarz et al., 2010). 
 
However, unlike the conventional idea that the epidermal Langerhans cells are the 
only langerin+ dendritic cells (DC) in the skin responsible for innate and adaptive 
immune responses, recent reports showed that langerin+ CD103+ dendritic cells also 
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reside in the dermis and induce immune response. In a study conducted in Wang et 
al, dermal langerin+ dendritic cells were found to have distinct biological functions to 
epidermal Langerhans cells and found to promote CD8 T cell response (Wang et al., 
2009). 
 
In addition, keratinocytes also play an important role in the skin immune system by 
producing cytokines including interleukin (IL)-1, IL-6, IL-7, IL-8, IL-10, interferon 
(IFN)-γ, tumour necrosis factor (TNF)- α and TGF-β that also participate in immune 
responses in the skin (Matsumura and Ananthaswamy, 2004). 
 
There are two major types of immune responses that UVR is known to suppress: 
contact hypersensitivity reactions (CHS) (Jessup et al., 1978) and delayed type 
hypersensitivity reactions (DTH) to viral (Howie et al., 1986), bacterial (Jeevan et al., 
1989) and fungal antigens (Denkins et al., 1989). Both CHS and DTH are the main 
experimental models used to study UVR-induced immunosuppression. Initially, CHS 
study begins with the epicutaneous application of a contact sensitizer in the induction 
phase. This is followed by an elicitation phase where a further application several 
days later induces the elicitation of CHS response, resulting in an inflammatory 
response at sites not directly exposed to UVR. CHS is usually measured 
experimentally either by observing a change in skin colour or measuring the skin 
thickness. In DTH the same protocol is followed except that the antigen is more 
complex and is usually injected subcutaneously so that antigen presenting cells other 
than those in the skin are involved (Norval, 2006). 
 
UVR-induced immunosuppression is classified into local immune suppression and 
systemic immune suppression. Local immune suppression refers to the situation in 
which the antigen (or hapten) is applied directly to the UV-irradiated skin. Systemic 
immune suppression occurs when the immune response is elicited by antigen being 
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applied to a distant non-irradiated site as opposed to UV-irradiated site (Ullrich, 
2005). Thus the two terms are used to describe the site of irradiation with respect to 
antigen exposure, but not to describe whether the immune response generated is 
local or systemic.  
 
We have been interested in the mechanism by which in vivo UV irradiation initiates 
immunosuppression. Because the wavelengths responsible (250 to 320 nm) do not 
penetrate beyond the skin, the sequence of events leading to systemic immune 
suppression must be initiated by the absorption of UVR by some moiety in the skin 
(De fabo and Kripke, 1980; Noonan et al., 1981). Recent findings suggest the role of 
IL-10 in immunosuppressive effects. When cytotoxic T-lymphocyte associated 
protein (CTLA)- 4 (CD152) positive T cells were stimulated in vitro, a variety of 
cytokines including IFN-γ, TGF-β, IL-2, and IL-10 were secreted. However, only IL-10 
monoclonal antibody neutralised the suppressive activity in vivo, suggesting that 
CTLA-4 positive suppressor T cells suppress contact hypersensitivity reactions by 
releasing IL-10 in vivo (Ullrich, 2005). 
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1.2.10 PHOTOCARCINOGENESIS 
Carcinogenesis is the result of complex molecular and biochemical events that 
eventually lead to the development of cancer. It is most frequently caused by 
carcinogens in the environment ranging from chemicals, radiation, viral or one’s own 
genetic susceptibility to cancer formation. These carcinogens are substances that 
interrupt the structure and function of the cell, ultimately leading to cancer 
development (McMillan, 1992). 
 
Figure 1.10 Initiation and progression of human squamous cell 
carcinoma (SCC). (Melnikova and Ananthaswamy, 2005) 
 
As shown illustrated in the Figure 1.8, carcinogenesis occurs in three stages: 
initiation, promotion and progression. Initiation commences with any chemical, 
physical or biological agent causing DNA damage, which may be reversible or lead 
to genetic mutation if not repaired. However, whether or not the mutation of the gene 
results in malignancy depends on the promotion stage. The promotion stage is the 
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result of the second factor, known as promoter, acting on the initiated cell causing 
selective clonal expansion of the initiated cells due to altered expression of those 
genes associated with hyperproliferation. However, there are carcinogens called 
complete carcinogens that could both initiate and promote neoplastic transformation. 
The third stage is the progression that involves morphological and phenotypic 
changes in the cell, specifically the development of preneoplastic cells into tumours 
through clonal expansion, which is facilitated by altered gene expression and 
progressive genomic instability. It is also associated with increased malignancy, 
leading to invasion of surrounding tissue and metastasis to distant body parts 
(Hursting et al., 1999; McMillan, 1992; Melnikova and Ananthaswamy, 2005) 
 
Unlike typical carcinogens, UVR acts as a complete carcinogen, having the ability to 
cause skin cancers without additional initiators or promoters (Melnikova and 
Ananthaswamy, 2005). Although UVR-induced skin carcinogenesis begins with DNA 
damage, it is the cascade of subsequent molecular and biochemical events that 
leads to cancer formation.  
 
One important part of tumour progression is the inactivation of one or more of tumour 
suppressor genes or over activation of proto-oncogenes. Inactivation of tumour 
suppressor genes might occur due to the accumulation of proteins that bind to 
tumour suppressor genes, hindering their ability to regulate cellular growth and 
making the cells more susceptible to further mutations. On the other hand, 
oncogenes are genes that normally control cellular proliferation and differentiation, 
yet become ‘proto-oncogenes’ when expressed excessively. In both cases, the 
resultant altered gene product could cause cancer formation. The genes worthy of 
discussion in the context of photocarcinogenesis are p53 and Ras gene, of which 
Ras gene was outside the scope of this study. (Matsumura and Ananthaswamy, 
2002).  
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Normally, when the cells have DNA damage there is an increase in p53 
phosphorylation and translocation to the nucleus that facilitates DNA repair or causes 
apoptosis of cells with severely damaged DNA. However, with excessive UVR 
exposure, such DNA repair mechanisms are disrupted, leading to p53 mutations, 
thereby allowing damaged cells to resist apoptosis (Ziegler et al., 1994). Thus the 
p53 mutation is the key initiating step of skin carcinogenesis, and the significance of 
p53 gene mutation has been illustrated through the finding that the number of UVR-
induced squamous cell carcinoma (SCC) is increased in the skin of p53 knockout (-/-
) mice (Ziegler et al., 1994). By extrapolation, the cells containing inactivated p53 due 
to mutations would have a reduced capacity to remove potentially mutagenic cells. 
More specifically, p53 activates cell cycle arrest and programmed cell death to 
eliminate such cells prior to replication. This is a crucial step in preventing skin 
carcinogenesis as cells with DNA damage could survive otherwise and develop into 
mutagenic cells (Hartwell and Weinert, 1989). This is further supported by a study 
involving p53-/- and p53 +/- mice, which showed increased sensitivity towards UVR-
induced skin tumour development compared with the wild-type mice. Heterozygous 
mice showed greater susceptibility to skin cancer induction compared with wild-type 
mice, and homozygous mice were even more susceptible (Jiang et al, 1999). 
 
The p53 mutation has been found in more than 90% of SCC occurrences (Ziegler et 
al., 1994). 
 
1.2.11 BODY’S DEFENCE AGAINST UVR 
Stimulation of p53 tumour suppressor protein effectively inhibits photocarcinogenesis 
by enhancing the nuclear excision repair of UVR-induced damage (Yamaguchi, 
2006). 
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1.2.11.1 SKIN PIGMENTATION 
Following the exposure to UVR, pigmentation occurs in the skin, consisting of two 
phases: immediate pigment darkening (IPD) and a delayed formation of new 
melanin.  
 
In immediate pigment darkening, pre-existing melanin undergoes oxidation and 
melanocytic melanosomes redistribute themselves from a perinuclear position into 
the peripheral dendrites, possibly providing a protection against damage to epidermal 
basal cell nuclei. This immediate pigment darkening may last from minutes to several 
days depending on the exposure dose. 
 
Delayed formation of new epidermal melanin is generally called ‘tanning’ and 
appears about 72 hours after exposure to UVB. On the other hand, with UVA 
exposure, tanning occurs much earlier with almost no latency, suggesting that the 
mechanism of melanin synthesis is different to that after UVB exposure.  
 
With shorter wavelengths UVB exposure, the number of melanocytes and 
melanocyte tyrosinase activity increase accelerates the melanin transfer to 
keratinocytes of upper epidermal layers. With UVA exposure, increase in melanin 
density is dependent on the wavelengths. For instance, UVA between 320 to 340 nm 
stimulates the synthesis and migration of melanised melanosomes to the upper 
layers, yet with UVA between 340 to 400 nm, increase in melanin density takes place 
in the basal cell layer (McGregor, 1999). 
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1.2.11.2 CORNIFICATION 
Cornification is the final process of keratinocyte differentiation that occurs naturally 
yet can be regulated by various factors upon extrinsic and intrinsic stimulations. As 
mentioned before, corneocytes – terminally differentiated keratinocytes, form the 
outermost layer of the epidermis, stratum corneum, which provides natural defence 
against UVR. Cornification process takes about 2 weeks and as a result, the 
keratinocytes become metabolically inactive and the organelles are degraded. The 
resulting fully differentiated squames are flattened dead cells that resemble ‘protein 
sacs’ consisting of more than 80% keratins crosslinked to other cornified envelope 
proteins. These corneocytes are ultimately sloughed into the environment and are 
replaced by differentiating keratinocytes from the inward layers (Lippens et al., 2005). 
 
Figure 1.11 Cornification process in skin. (Lippens et al., 2005) 
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1.3 VITAMIN D 
1.3.1 GENERAL BACKGROUND 
Sir Edward Mellanby first recognized vitamin D2 in 1919, when his suggestion that 
rickets could be caused by a nutritional deficiency led to the isolation of a fat-soluble 
antirachitic substance in fish liver oil and other foods, which was identified as vitamin 
D2 (Mellanby, 1919). This work and continuing study led to the structural 
identification of vitamin D2 and vitamin D3. Since the discovery, the physiological 
significance of vitamin D has been growing with particular attention to its regulatory 
role in bone and mineral metabolism on top of other endocrine functions in humans. 
 
Vitamin D is a secosteroid cholesterol derivative in which one of its rings has 
undergone breakage (ring B in the case of vitamin D). This family has different 
geometric forms, where each member has its own unique structural features. The 
hormonally active form, 1α,25-hydroxy(OH)2 vitamin D3, otherwise known as 
1,25(OH)2D3 is the major metabolite of vitamin D3 (Reichel et al., 1989). 
 
1.3.2 STRUCTURE 
As mentioned before, 1,25(OH)2D3 is a secosteroid, having similar structure to 
classical steroid hormones. Vitamin D and all its metabolites, including the steroid 
hormone 1,25(OH)2D3 are, in comparison to other steroid hormones, unusually 
conformationally flexible. This flexibility is due to three particular features of the 
molecule (shown in figure 1.10): 
i. First is that the side chain has a 360° rotation around each of the 5 carbon-
carbon single bonds.  
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ii. the A-ring undergoes a cyclohexane-like chair–chair immersion, which 
changes the orientation of 1α-hydroxyl and 3β-hydroxyl groups between the 
equatorial and axial orientations.  
iii. the broken B-ring has a 360° rotation around the 6,7 single carbon bond.  
 
 
Figure 1.12 Structure and the conformational flexibility of 1,25(OH)2D3. 
(Norman et al., 2002) 
This conformational flexibility allows a wide array of molecular shapes that are 
available for binding to receptors involved with 1,25(OH)2D3 mediated biologic 
responses (both genomic and non-genomic) as well as for binding to DBP and 
cytochrome P450 enzymes (Norman et al., 2002). 
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1.3.3 VITAMIN D RECEPTOR (VDR) 
The Vitamin D receptor (VDR) is an intracellular nuclear receptor, which is a member 
of the steroid-thyroid hormone receptor superfamily (Petrazzuoli, 1999). As with other 
nuclear receptors, VDR has a transcriptional activation domain, a specific DNA-
binding domain that is rich in cysteine, and a specific ligand binding domain (Fig 
1.11). 
 
Figure 1.13 The structure of Vitamin D receptor. (Haussler et al, 2011) 
DBD (DNA binding domain), CTE (C-terminal extensions). 
 
The VDR is responsible for both the genomic and non-genomic pathways of action 
for which it contains a genomic pocket (VDR-GP) and an alternative pocket (VDR-
AP). (Haussler et al., 2011) 
 
1.3.4 BIOSYNTHESIS AND METABOLISM 
Vitamin D3 in its active form, 1α,25(OH)2D3, is synthesised after a number of 
reactions within human’s body. Its precursor is 7-dehydrocholesterol (7-DHC) that is 
converted into the pre-vitamin D3 upon UVB absorption. Then by thermal 
isomerisation at the body temperature, pre-vitamin D3 is converted into vitamin D3 
over several hours. However, this is still an inactive form of vitamin D3 that must be 
converted into the active form to induce any biological responses. First, vitamin D3 
binds to the vitamin D binding protein (DBP) in the blood to enter the circulation 
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(Norman et al., 2001a). Then vitamin D3 undergoes two sequential hydroxylations by 
cytochrome P450 enzymes. It is firstly hydroxylated by 25-hydroxylase in the liver to 
form 25-hydroxyvitamin D3 (25(OH)D3). This is then hydroxylated again by 1α-
hydroxylase, mostly in the kidney but also in other tissues, into 1,25(OH)2 D3. This is 
illustrated in figure 1.12. 
 
Vitamin D is an essential hormone that enables the absorption of calcium in the 
intestinal mucosa. 
 
 
Figure 1.14 Schema of vitamin D metabolism. (Brown et al., 1999) 
 
1.3.5 MECHANISMS OF ACTION 
The active vitamin D metabolite, 1,25(OH)2D3 generates physiologic effects at a 
cellular level, by binding to the ligand binding pockets on the nuclear vitamin D 
receptor (VDR). There are two mechanisms of its action, a genomic pathway that 
regulates gene transcription, and a non-genomic pathway that involves cellular 
cytoplasmic signalling pathways.  
 37 
 
1.3.5.1 GENOMIC PATHWAY 
As mentioned earlier, genomic pathway of vitamin D signalling involves the activation 
of transcriptional complexes that target specific genes in the DNA sequence. As a 
DNA-binding transcriptional factor, 1α,25(OH)2D3 -bound VDR first binds to retinoid X 
receptor (RXR), making a heterodimeric protein. This liganded-VDR and RXR forms 
a complex that has a combined DNA binding domain (DBD) zinc fingers to recognize 
vitamin D responsive elements (VDREs) in the DNA sequence of vitamin D regulated 
genes. These may be in the promoter region of target genes or at distant enhancer 
or repressor sites. Following VDRE docking, protein co-activators (or co-repressors) 
are recruited to interact with VDR-RXR complex in order to either promote or repress 
gene transcription (Haussler et al, 2011; Zella et al, 2010). 
 
1.3.5.2 NON-GENOMIC PATHWAY 
Non-genomic pathway, or the rapid-acting pathway for the action of 1,25(OH)2D3 has 
been known to induce various biological processes within seconds to minutes via 
intracellular signalling pathways, though the receptor involved in this pathway has not 
yet been definitively identified. The pathway is often referred to as ‘rapid-acting’ 
because the responses are generated within 1-2 min to 15-45 min, which is in 
contrast to genomic responses that take hours to days to be fully apparent (Haussler 
et al, 2011). 
 
The binding of 1,25(OH)2D3 to its proposed rapid-response receptor can stimulate 
various intracellular signalling pathways including protein kinase C (Nemere et al. 
1998), cAMP, intracellular calcium, and MAP kinase, phosphatidylinositol 3-kinase 
(PI3K), phospholipase C and subsequent G-protein coupled second messenger 
systems (Norman, 2008).  
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There is evidence of a membrane-associated rapid response steroid-binding protein 
(1,25D3 -MARRS), one that is identical to endoplasmic reticulum stress protein 57 
(ERp57), as the receptor involved in non-genomic actions by 1,25(OH)2D3. Previous 
studies have shown that in the presence of Ab099, a neutralizing antibody against 
the N terminus of ERp57, 1,25(OH)2D3-mediated effects such as augmented 
intracellular calcium and protein kinase C activity were abolished in chick intestinal 
epithelial cells (Nemere et al., 2000; Nemere et al., 2004). Also, recent studies have 
reported that when normal fibroblasts were pretreated with Ab099, protective effect 
of 1,25(OH)2D3 against UVR-induced thymine dimers was abolished (Sequeira et al., 
2012). This evidence implicates ERp57 as a necessary component of 
photoprotection by 1,25(OH)2D3, suggesting that ERp57 mediates at least some of 
the nongenomic actions 1,25(OH)2D3.  
 
In addition, opening of chloride channels has recently been reported to be another 
possible non-genomic pathway of 1,25(OH)2D3-induced protection against thymine 
dimers formation in keratinocytes. Treatment with DIDS (4,4’-
diisothiocyanatostilbene-2,2’-disulfonic acid), a chloride channel blocker, which was 
shown to have no effects on thymine dimers on its own, completely prevented the 
protective effects of 1,25(OH)2D3 when they were used together (Sequeira et al., 
2013).  
  
As mentioned previously, the conformational flexibility of 1,25(OH)2D3 plays an 
important role as it allows 1,25(OH)2D3 a wide variety of different shapes to serve as 
ligands for available receptor(s) in the vitamin D endocrine system.  
 
The evidence reported support the view that the VDR and the receptor/binding 
domain involved in rapid responses recognize different shapes of 1,25(OH)2D3, 
thereby enabling 1,25(OH)2D3 to interact with its receptors in all of its many target 
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cells. By extrapolation, this hypothesis also suggests that conformationally flexible 
analogues of vitamin D can theoretically, initiate either genomic or rapid, non-
genomic biological responses.  
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1.3.6 VITAMIN D3 REGULATED KERATINOCYTE DIFFERENTIATION 
Vitamin D3 in its active form is also known to have various other biological roles. One 
important process that it regulates is keratinocyte homeostasis. Through genomic 
and non-genomic events, 1,25(OH)2D and calcium are known to regulate a decrease 
in keratinocyte proliferation whilst inducing an increase in morphologic differentiation 
of keratinocytes (Haake and Holbrook, 1999). 
 
Keratinocytes in the basal layer are able to synthesise 1,25(OH)2D3 from 7-DHC, yet 
at the same time, they are also the target for hormone. In addition, intracellular 
calcium is known to have potent effects on proliferation and differentiation as well. In 
number of in vitro studies, calcium has been shown to induce various signs of 
keratinocyte differentiation including cell to cell contact, desmosome formation and 
the upregulation of involucrin, transglutaminase, keratins and filaggrin expressions. 
Together, 1,25(OH)2D3 and calcium have their own mechanisms to create synergistic 
regulation of keratinocyte differentiation (Bikle, 2004). 
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1.3.7 PREVIOUS FINDINGS ON PHOTOPROTECTION BY VITAMIN D3  
It has been shown in the current research laboratory that 1,25(OH)2D3 protects 
against UVR-induced cell loss when it is applied to keratinocytes, melanocytes and 
fibroblasts prior to and/or immediately after UVR. In those skin cells, application of 
1,25(OH)2D3 diminished the level of cyclopyrimidine dimers, a major marker for 
photodamage, substantially in a dose-dependent manner and the survival rate of 
keratinocytes following UVB was improved upon addition of 1,25(OH)2D3 (Wong et 
al., 2004; Song et al., 2013). 
 
Although it has previously been found that the photoprotection by 1,25(OH)2D3 is 
chiefly due to its inhibitory effect on the formation of cyclopyrimidine dimers in human 
skin after UV exposure, it was found by our research group that DNA damage is not 
solely dependent on direct absorption of UVR by DNA. The damage is also found to 
be dependent on metabolic pathways, particularly the nitric oxide (NO) pathway. 
Nitric oxide is known to react with the UVR-induced reactive oxygen species that 
combine to excite an electron in fragments of the pigment melanin, forming “dark 
CPDs” previously mentioned in chapter 1.2.5.1 (Premi et al., 2015). This was also 
evident in Mason group’s finding, which demonstrated that 1,25(OH)2D3 suppresses 
various forms of promutagenic DNA damage, including thymine dimers, in part 
through a reduction of genotoxic reactive nitrogen species (RNS). This study further 
reinforced the suggestion that a reduction in reactive nitrogen species by 
1,25(OH)2D3 is a likely mechanism for its photoprotective effect against oxidative and 
nitrative DNA damage, as well as CPDs (Gordon-Thomson et al., 2012).  
 
There are other potential mechanisms including 1,25(OH)2D3 induced expression of 
metallothionein (MT), a potent radical scavenger. 1,25(OH)2D3 neither inhibited 
peroxidation of plasma lipids nor interacted with superoxide, nor removed hydrogen 
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peroxide as an antioxidant (Lee and Youn, 1998). These findings suggest that 
1,25(OH)2D3 has photoprotective effect not related with glutathione or its endogenous 
antioxidant property. Rather, it could be attributed to 1,25(OH)2D3-induced 
metallothionein and its capacity to prevent radical-related damage in UVB irradiation 
(Lee and Youn, 1998). 
 
1.3.8 VITAMIN D LIKE COMPOUNDS 
The discovery of the newer non-genomic functions of 1,25(OH)2 D3 led to a growing 
interest in the search for new vitamin D like compounds or analogues (Jones et al., 
1998). Some of the analogues discussed below include known agonists and 
antagonists of the rapid response pathway, and an antagonist of the genomic 
pathway. No specific agonist of the genomic pathway has been reported.  
 
1.3.8.1 JN: NON-GENOMIC AGONIST 
JN (1α,25(OH)2 -lumisterol) mediates its biological functions via the rapid, non-
genomic pathway. JN, a low-calcemic 6-s-cis-locked analogue, has been shown to 
be a full agonist of the non-genomic pathway and can only weakly bind to the VDR. It 
has also been known to be effective inhibitor of UVR-induced damage in an 
immunocompetent mouse (Skh:hr1) model susceptible to UVR-induced tumours. 
Photoprotection by JN was shown through reduction in UVR-induced cyclobutane 
pyridimine dimers, apoptotic sunburn cells, and immunosuppression (Normal et al., 
1997; Dixon et al., 2011). However, these markers of photoprotection do not 
necessarily imply that they inhibit skin carcinogenesis as they are the results of acute 
UVR exposure. 
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1.3.8.2 QW: LOW CALCEMIC ANALOGUE 
QW (1α-hydroxymethyl-16-ene-24,24-difluoro-25-hydroxy-26,27-bis-homovitaminD3 
or QW-1624F2-2) is transcriptionally active and is approximately 80-100 times less 
calciuric than 1,25(OH)2 D3 (Posner et al., 2004; Reddy et al., 2006). QW has high 
anti-proliferative and pro-differentiating activity and has been shown to inhibit 
chemical-induced skin tumourigenesis and tumour latency (Kensler et al., 2000). 
Furthermore, this hybrid analogue does not cause cachexia in animals (Posner et al., 
1998) and has been shown to be non-genotoxic (Posner et al., 2004). QW has been 
fast tracked by the United States Food and Drug Administration (U.S.F.D.A.) for 
approval for clinical use in humans. Recent studies have revealed that QW 
significantly reduced UVR-induced DNA lesions (CPD) in skin fibroblasts and 
keratinocytes and reduced cell death after UV exposure (Dixon et al., 2012). 
 
1.3.8.3 HL: NON-GENOMIC ANTAGONIST 
HL (1β,25(OH)2 D3 ) has been shown to selectively inhibit the functioning of the non-
genomic pathway (Norman et al., 1999). The employment of a non-genomic pathway 
antagonist in this project was crucial in the isolation of the pathway through which 
photoprotection is mediated. 
 
1.3.8.4 TEI-9647: GENOMIC ANTAGONIST 
TEI-9647 (25-dehydro-1α-hydroxyvitamin D3-26,23S-lactone; MK), acknowledged for 
its antagonistic effect on the genomic action of 1,25(OH)2D3 in human tissues (Bula 
et al., 2000; Ishizuka et al., 2001), was used in this study to assess the effects of 
inhibition of the genomic pathway on photoprotection by 1,25(OH)2D3. At high 
concentrations it is known to have some agonist activity. When used in combination 
with 1,25(OH)2D3, TEI-9647 did not inhibit the effect of 1,25(OH)2D3, as the degree of 
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UVR-induced cell loss was not significantly different to the level of loss in 
melanocytes treated with 1,25(OH)2D3 only. Also, TEI-9647 did not show significant 
antagonistic effect on photoprotection by 1,25(OH)2D3 in terms of UVR-induced 
cyclobutane pyrimidine dimers (CPDs). The proportion of positive CPDs staining in 
melanocytes treated with a combination of TEI-9647 and 1,25(OH)2D3 did not differ 
from that in cells treated with 1,25(OH)2D3 alone. Similar results were observed in 
fibroblasts, where a significant reduction in cell loss and photoprotective action by 
1,25(OH)2D3 were maintained in the presence of TEI-9647 (Dixon et al., 2005). 
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1.4 20-HYDROXYVITAMIN D3 (20(OH)D3 ) 
1.4.1 BACKGROUND 
20-hydroxyvitamin D3 is a product of vitamin D3 hydroxylation by an enzyme called 
cytochrome P450scc (or CYP11A1), which normally performs cholesterol side chain 
cleavage on 7-dehydrocholesterol or cholesterol (Slominski et al., 2005b). The 
expression of CYP11A1 enzyme was shown to be increased in both human 
keratinocytes and melanocytes after UVR exposure (Skobowiat et al., 2011). 
1.4.2 STRUCTURE 
 
Figure 1.15 Structure of 20(OH)D3. (Zbytek et al., 2008) 
 
1.4.3 EVIDENCE SUGGESTING PHOTOPROTECTIVE EFFECTS OF 20-
HYDROXYVITAMIN D3. 
It has been shown that the active form of vitamin D, 1,25-dihydroxyvitamin D3 
(1,25(OH)2D3) protects skin cells from mutagenic DNA damage and 
photocarcinogenesis (Dixon et al., 2011). In experiments involving vitamin D receptor 
knockout mice, it was shown that these mice became more susceptible to 
carcinogenesis upon UV irradiation (Ellison et al., 2008). However, it was also found 
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that knockout of 1α-hydroxylase enzyme (CYP27B1), an enzyme essential for the 
production of 1,25(OH)2D3, does not increase the susceptibility to 
photocarcinogenesis (Teichert et al., 2011), This led to the question whether other 
vitamin D metabolites, specifically 20-hydroxyvitamin D3 (20(OH)D3), which is made 
naturally in irradiated skin from vitamin D by the CYP11A1 enzyme, could play a role 
in photoprotection. 
 
Also, a study has been done on human epidermal keratinocytes to observe the effect 
of 20(OH)D3 on the genes involved in keratinocyte differentiation. For instance, a 
study has been done to show that the expression of involucrin mRNA increased upon 
treatment with 20(OH)D3. The stimulating effect of 20(OH)D3 did not stop at the 
transcriptional level but was found that this stimulation was reflected in the 
keratinocyte phenotype, hence confirming that 20(OH)D3 is a stimulant of involucrin 
expression (Zbytek et al., 2008). As involucrin is an important protein involved in 
cornification of keratinocyte, one of protective mechanisms within human’s body, it 
can be inferred that 20(OH)D3 could affect genes that could provide photoprotective 
capacity to skin cells.  
 
In addition, antitumour activities of 20(OH)D3 has been shown previously on cancer 
cell lines such as breast carcinoma cells and hepatocellular carcinoma cells. 
Although these cell lines have different metabolism and machinery in nature to skin 
carcinoma cells, these evidences strongly suggest potential antitumour activity of 
20(OH)D3 on skin cell lines as well (Wang et al., 2012). 
 
Lastly, it was shown in the short terms studies by our colleagues that 20(OH)D3 like 
1,25(OH)2D3 and at similar concentrations, reduced CPD and 8-oxodG in UV-
irradiated human keratinocytes. They also found that 20(OH)D3 reduced UVR-
induced skin oedema measured as dorsal skin-fold thickness in UV irradiated mice 
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(p<0.01) and significantly reduced UVR-induced immunosuppression in these mice, 
measured by contact hypersensitivity from 35% in vehicle treated mice, to under 5% 
in mice treated with 20(OH)D3, to a similar extent as 1,25(OH)2D3 (p<0.001 vs 
vehicle). (Tongkao-on et al., 2015). 
 
On the other hand, studies on photoprotective effect of 20(OH)D3 on HaCaT cell line 
are incompletely understood. There are however, some studies suggesting that there 
is a limitation of HaCaT cell line as a model to study photoprotection. Firstly, HaCaT 
cell lines have mutated p53, tumour suppressor gene that is known to play a 
significant role in regulating DNA repair after UVR exposure in keratinocytes as 
explored by the Mason group (Section 1.2.7). Although we do not have direct 
evidence suggesting that 20(OH)D3 increases nuclear p53 expression, it is 
reasonable to assume that DNA repair pathways following UVR exposure in HaCaT 
cell lines will be different, and thus difference in photoprotective mechanisms 
between primary keratinocytes and HaCaT cell line. In addition, recent study found 
that gene transcriptional profile of cornified envelope-associated proteins, such as 
filaggrin, loricrin, involucrin and keratin 10, in response to major helper T cell 
cytokines such as IL-17 and IFN-! , are different from that in normal human 
keratinocytes. This also suggests a limitation in HaCaT cell line as a model to study 
chronic inflammation and skin barrier function as they respond differently to 
inflammatory cytokines when compared to normal keratinocytes (Seo et al., 2012). 
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1.5 PROJECT 
1.5.1 AIMS AND HYPOTHESES 
 
Aims: 
1) To examine the effects of 20(OH)D3 and 1,25(OH)2D3 on the viability of the 
immortalised human keratinocyte cell line, HaCaT, and of primary keratinocytes 
in culture after UV exposure. 
2) To examine whether 20(OH)D3, with 1,25(OH)2D3 as a positive control, would 
alter UV-induced skin tumour formation and chronic immunosuppression in 
Skh:hr1 albino female mice. 
 
Hypotheses to be tested:  
a) That 20(OH)D3, like 1,25(OH)2D3, protects human keratinocytes against UVR-
induced damage, but that this protection is not observed in HaCaT cells, often 
used as a model for primary keratinocytes. 
b) That 20(OH)D3, like 1,25(OH)2D3, will reduce skin tumour formation, and 
chronic immune suppression in a mouse photocarcinogenesis model. 
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2 MATERIALS AND METHODS 
2.1 MATERIALS 
2.1.1 EQUIPMENT 
A sterile experimental environment for cell culture was provided by a Class II 
biohazard laminar flow cabinet obtained from Gelman Sciences Pty Ltd (Sydney, 
Australia). 
 
Cells were stored in a liquid nitrogen Dewar purchased from Taylor-Wharton 
Australia (Albury, Australia). The centrifuge was purchased from Hettich Zentrifugen 
(Tuttlingen, Germany). Cells were incubated in a water-jacketed incubator with 
controlled CO2 atmosphere from Forma Scientific (Sydney, Australia). Cells were 
regularly monitored under a phase-contrast inverted microscope (Olympus model 
IMT-2) from Olympus Optical Co Ltd (Tokyo, Japan). Cells were manually counted 
using a Neubauer chamber haemocytometer from Superior (Germany). Solutions 
were filtered using Sterivex™ 0.22 µm filter unit from Millipore (Billeria, MA, USA). 
 
2.1.2 GENERAL CHEMICALS AND REAGENTS 
Aqueous solutions were prepared using MilliQ purified water, provided by the Bosch 
Molecular Biology Facility (University of Sydney, Australia). 
Chemicals and solvents including 1,2-propanediol were purchased from Sigma-
Aldrich (St Louis, MO, USA) unless otherwise stated. 
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2.1.3 VITAMIN D COMPOUNDS 
1,25(OH)2D3 was purchased from Sigma Aldrich (St Louis, MO, USA). 20(OH)D3 – a 
gift from Dr. Robert Tuckey, UWA. These compounds were dissolved in 
spectroscopic ethanol and were stored under argon at -80°C. 
 
The quality of vitamin D compounds was checked by measuring absorbance peaks 
using a spectrophotometer. This is shown in Figure 2.1 and Figure 2.2. 
 
Figure 2.1 Spectrophotometric analysis of 1,25(OH)2D3 
Wavelength (nm) 
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Figure 2.2 Spectrophotometric analysis of 20(OH)D3. (image courtesy of 
colleague, Bianca McCarthy) 
 
2.1.4 COMPOSITION OF MEDIA AND SOLUTIONS 
HaCaT Growth Medium 
HaCaT cells were grown in a medium consisting of normal calcium and glucose 
Dulbecco’s Modified Eagle Media (DMEM). 
 
Keratinocyte growth medium (KGM) 
Keratinocytes were grown in Dulbecco's modified Eagle's medium (DMEM) 2.2g/L 
NaHCO3, 0.293g/L glutamine, 2.385g/L HEPES, 0.03g/L penicillin, 0.05g/L 
streptomycin, and 5% v/v FBS, without calcium, pH 7.4. Growth supplements added 
to KGM included 10ng/mL epidermal growth factor (EGF), 500µg/L Hydrocortisone 
and 10-10 M cholera toxin.  
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Martinez Solution 
8.4738g/L NaCl, 0.41g/L KCl, 0.244g/L MgCl2.6H2O, 0.1872g/L NaH2PO4.2H2O, 
1.9523g/L NaHEPES, 1.7873g/L HHEPES, 0.147g/L CaCl2.2H2O, 1.8016g/L D-
glucose, pH 7.4.  
 
0.1 % Trypsin / 0.2% EDTA 
0.2 g/L EDTA, 1g/L D-glucose, 0.4g/L KCl, 8g/L NaCl, 0.580g/L NaHCO3, 1g/L 
trypsin in MilliQ water. 
 
Cell lysis buffer 
Cell were lysed using a lysis buffer containing 1.21g/L Tris buffer, 8.77g/L NaCl, 
0.5% SDS, 1% Triton X-100, 292.2g/L EDTA, 0.0168g/L NaF, H2O and protease 
inhibitor which was added immediately prior to lysing the cells. Cell lysis buffer was 
made fresh on the day prior to use. 
 
Base lotion for in vivo treatments 
The base lotion for in vivo treatments consisted of spectroscopic ethanol, and 1,2-
propanediol (propylene glycol) and MilliQ water to a final solvent ratio of 2:1:1, 
respectively. Base lotion was prepared in a 50 mL container and stored at room 
temperature under normal laboratory conditions.  
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2.2 METHODS FOR IN VITRO STUDIES WITH HACAT CELLS 
AND KERATINOCYTES 
2.2.1 SOURCE OF TISSUE 
Primary keratinocytes used for cell culture studies were obtained from neonatal 
foreskins donated after circumcision, with parental consent. Skin samples arrived at 
4ºC in a serum-free medium containing streptomycin and penicillin, and were 
refrigerated at 4ºC upon receipt. Primary keratinocyte collection was conducted 
within 48 hours of circumcision surgery. All studies were conducted with the approval 
of the University of Sydney Human Research Ethics Committee (protocol number 
14751) and Sydney South West Area Health Service (protocol number X09-0069). 
 
HaCaT cells were donated from Professor Gary Halliday, University of Sydney (with 
permission from the originator). 
2.2.2 GENERAL CELL CULTURE 
Cell culture was conducted in a Class II biohazard laminar flow cabinet under sterile 
conditions (by UV radiation). Solutions including media, PBS and trypsin were pre-
warmed in a heating water bath to room temperature prior to use. 
 
2.2.3 PRIMARY KERATINOCYTE CULTURE 
Primary keratinocytes were processed as previously described by Gupta and Dixon 
et al. (2007) from donated neonate foreskin samples under aseptic conditions in a 
Class II biohazard laminar flow cabinet, and all solutions used were sterile. Each 
foreskin sample was washed with 70% ethanol twice, after discarding the original 
media. The samples were further washed in PBS containing penicillin and 
streptomycin for 3 minutes, followed by another 3 minutes in PBS without the added 
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antibiotics. Following the initial washing of the samples, the subcutaneous tissue 
was removed and each sample was cut into small pieces approximately 3x3mm, 
before briefly submerging the pieces in betadine antiseptic solution and rinsing in 
PBS. The skin pieces were incubated at 4°C in 0.1% dispase (w/v) in PBS for 
approximately 24 hours to facilitate the separation of the epidermal and dermal 
layers.  
 
The following day, the epidermis was removed with forceps and incubated briefly at 
37°C in a solution of 0.1%/0.02% Trypsin/EDTA (w/v) in PBS in order to form a cell 
suspension. The trypsin was neutralised using a medium containing serum and 
calcium, the cell suspension was then centrifuged at 2000 rpm for 8 minutes. The 
resulting cell pellet was resuspended in KGM containing 5% FBS and the cells were 
cultured in a 75 cm2 culture flask. Cells were grown at 37°C and 5% CO2 in a 
humidified cell culture incubator. The medium in each culture flask was aspirated 
three times weekly and replaced with fresh medium. The condition of cells was 
monitored regularly via a phase-contrast microscope. 
 
2.2.4 CULTIVATING CELLS 
For cell growth and proliferation, HaCaT cells were cultured in DMEM with 10 % FBS 
(v/v) and the keratinocytes were cultured in KGM with 5% FBS. These cells were 
incubated under 37°C and 5% CO2 gas and the growth medium was replaced every 
second or third day since culturing (or subculturing). Cell cultures were monitored 
regularly by using a phase contrast microscope to ensure growth, the absence of 
contaminants and to check for cell confluency. HaCaT cultures usually reached 90-
100% confluency within 2-3 days. 
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2.2.5 CELL HARVESTING BY TRYPSINIZATION 
Cells were harvested by applying trypsin, allowing cells to be detached from the flask 
surface by enzymatic cleavage. Prior to trypsinizing the cells, all culture medium was 
aspirated and the inside of the flask was washed with Dulbecco’s PBS (D-PBS) in 
order to remove remaining traces of medium that could inhibit trypsinization. Trypsin 
stock solution containing 4 mL of D-PBS and 1 mL of 0.1% trypsin was added to the 
flask, prior to incubation for approximately 5-10 minutes at 37°C for trypsin 
activation. Incubation time may vary depending on the degree of cell adhesion and 
confluency. Cells were viewed under the microscope after approximately 5 minutes 
in order to examine the degree of cell detachment. The trypsinization period should 
be kept to a minimum to prevent potential damage to the cell membrane. The flask 
was gently tapped to help detach and suspend cells. 
 
The cell suspension was then transferred to a centrifuge tube in a laminar flow hood, 
before being centrifuged at 1200 rpm for 5 minutes at room temperature. The 
supernatant was discarded and the cell pellet was resuspended with the appropriate 
cell culture medium. 
 
After trypsinizing and resuspending the cells, the resulting cell suspension could be 
used to perform subculturing, cell freezing and cell plating. Before these processes 
were performed, a manual cell count was conducted using Neubauer Chamber 
(hemocytometer) when necessary. 
 
In general, the cell trypsinizing process could be repeated several times according to 
the cell passage number limits. However, as HaCaT cells are an immortalized cell 
line, they do not undergo cell senescence and as a consequence, cell passage could 
be conducted numerous times. Primary cells have a lower number of permitted 
passages, in the case of keratinocytes a maximum passage number of 5 is 
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permitted, and cells grown past this passage number have a lower viability. For this 
reason, experiments with keratinocytes were conducted at low passage number.  
 
2.2.6 CELL PASSAGING (SUBCULTURE) 
Typically, when cells reach approximately 70% or greater confluency, subculturing 
was necessary in order to prevent cell apoptosis, cell death associated with high cell 
density within the culture flask. This process was performed after trypsinizing and 
resuspension of the cells as described in Section 2.3.4. To subculture the cells 8 mL 
of cell suspension was discarded and the remaining 1 mL resuspended with DMEM 
(or KGM with keratinocytes) to make up a total of 10 mL growth medium in the 
culture flask. 
 
2.2.7 CRYOPRESERVATION 
Before cryopreservation (freezing), cells were first trypsinized as described in 
Section 2.3.4.and then resuspended in an ice-cold freezing solution containing 
DMSO, and frozen down in a cryovial at –80°C. Keratinocytes were frozen in 5% 
DMSO (v/v) diluted in KGM with 20% FBS (v/v).  
Cells treated in this manner can be stored at –80°C for no less than 24 hours and up 
to 7 days before transferring to a liquid nitrogen Dewar (-196°C) for long term 
storage. 
 
2.2.8 RECOVERY FROM CRYOPRESERVATION 
Frozen down cells stored in a liquid nitrogen dewar were thawed and transferred 
directly into a centrifuge tube containing approximately 4 mL of appropriate growth 
medium. The suspension was then centrifuged and the supernatant containing 
DMSO was discarded. The cell pellet was then resuspended with the appropriate 
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growth medium and was immediately placed in a culture flask containing the 
appropriate growth medium. 
 
2.2.9 PLATING CELLS FOR EXPERIMENTATION 
Keratinocytes of passage 1-3 were seeded onto plates upon reaching 70-80% 
confluence, whilst HaCaT cells were seeded regardless of their passage number. 
Cells were plated in the appropriate plates and allowed 48 hours to attach prior to 
irradiation and treatment. 
 
Two plate sizes were used in in vitro studies: sterile 96 well-plate for used for cell 
viability assays. One 96 well plate containing both sham-irradiated and UVR-
irradiated groups was used for conducting the cell viability assay. Keratinocytes were 
seeded at a density of approximately 20,000 cells per well whilst HaCaT cells were 
seeded at approximately 10,000 cells per well. 
 
The respective medium without supplements but containing the appropriate 
concentration of FBS for each cell type was replaced in all wells 24 hours before 
irradiation. This allows the cell signalling pathways to stabilise.  
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2.2.10 ULTRAVIOLET RADIATION SOURCE 
The UVR source for in vitro studies consisted of one UVA and one UVB lamp, with 
irradiance of 203 mJ/cm2 UVB and 1168 mJ/cm2 UVA (Philips, Amsterdam, Holland), 
filtered through 0.5 mm cellulose tri-acetate (Eastman Chemical Products, Kingsport, 
TN) to remove wavelengths below 290 nm as previously described (Dixon et al., 
2011). Irradiance was checked regularly with an OL754 spectroradiometer 
(Optronics Laboratories Inc., Orlando, FL).  
 
Figure 2.3 Irradiance output of UV lamps used in cell culture studies 
with and without cellulose acetate filter 
Output of UV lamps is shown with and without cellulose acetate filter, as measured 
with the OL754 spectroradiometer. 
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2.2.11 ULTRAVIOLET IRRADIATION 
When the plated cells reached appropriate confluency (approximately 70-80%), they 
were ready to be irradiated; this was typically within 48 hours of replacing medium 
with medium without supplements. 
 
Equipments for UVR were set up in a laminar flow hazard hood to allow sterile 
conditions and temperature stability as shown in Figure 2.4. Prior to irradiation, cell 
medium was replaced with Martinez buffer solution containing D-glucose, a solution 
that does not absorb light in the UV spectrum whilst maintaining necessary nutrient 
levels for the cells during the period of irradiation. As shown in Figure 2.4, both 
plates equally received cellulose acetate filtered UVR and cells were irradiated on a 
turntable and plates rotated 180° halfway through the irradiation procedure to ensure 
even UVR exposure throughout the multi-well plate. For sham-irradiated group, the 
plate was covered with aluminium foil whilst UVR-irradiated group was not.  
 
Immediately following the irradiation, Martinez solution was aspirated from each well 
and replaced with media containing vehicle, 1,25(OH)2D3 or 20(OH)D3.  
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Figure 2.4 UV irradiation set up for cell culture studies 
Equipments include, turntable, cellulose acetate filter, UV lamps, aluminium foil, cell 
culture plate. 
 
2.2.12 TREATMENTS 
Vehicle treatment was made by mixing 1 µL of spectroscopic ethanol with 999 µl cell 
growth medium. 1,25(OH)2D3 treatment was made by mixing 1 µL of 10-6 M 
1,25(OH)2D3 stock solution with 999 µL cell growth medium to make a final 
concentration of 10-9 M. 20(OH)D3 treatment was made by mixing 1 µL of 10-6 M 
20(OH)D3 stock solution with 999 µl cell growth medium. 
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2.2.13 CELL VIABILITY ASSAY 
In order to assess cell viability, cell titer blue assay was chosen, an assay that 
provides a homogenous, fluorescent method for monitoring cell viability. This assay 
is based on the ability of metabolically active cells to convert a redox dye (resazurin) 
into a fluorescent end product (resorufin). Nonviable cells would not generate 
fluorescence as they have lost metabolic activity. The cell titer blue assay was 
conducted according to the manufacturer’s protocol (Promega, Madison, WI, USA). 
 
First, the cells that were grown in culture flasks were trypsinized as explained in 
Sections 2.3.4 and 2.3.5. Then these cells were seeded onto 96-multi well plates as 
shown in Section 2.3.10. Then the cells were handled for UVR protocol as explained 
in Section 2.3.12. Once the UV irradiation protocol was finished, cells were 
immediately treated with the treatments and incubated for at least 24 hours at 37°C. 
Then the cell titer blue solution was thawed, and 10 µL of it was added to each well 
containing the cells. This was incubated for at least 90 minutes and up to 4 hours at 
37°C. After the incubation period, the cell medium in each well was pipetted and 
transferred to a black well plate for fluorescence reading. 
 
The fluorescence reading was achieved using the BMG Fluostar Galaxy Plate reader 
in Bosch Molecular Biology Facility (University of Sydney, Australia). 
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2.2.14 STATISTICAL ANALYSIS 
For in vitro studies with HaCaT cells and keratinocytes, results are based on 
quadruplicates of each treatment, and are presented as either single experiments, 
expressed as mean ± 1 standard deviation, or as normalized data from more than 
one experiment, expressed as mean ± SEM. Standard error of mean and 
coefficients of variation of percentage cell survival were calculated using the 
coefficients of variation of each mean by the method of Colquhoun (Colquhoun, 
1971).  
 
For both in vitro studies, comparisons between treatment groups were made by one-
way analysis of variance (ANOVA) followed by Dunnett’s test using the GraphPad 
Instat statistical program (GraphPad Software Inc., San Diego, CA).  
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2.3 METHODS FOR IN VIVO STUDIES WITH SKH:HR-1 MICE 
2.3.1 ANIMALS AND MAINTENANCE 
In vivo studies were conducted on a total of 100 inbred female Skh:HR-1 albino 
hairless mice, aged 6 weeks at commencement of the experiment. These mice were 
provided by Associate Professor Vivienne Reeve from the Faculty of Veterinary 
Science (University of Sydney, Australia). Animal husbandry was provided by 
Laboratory Animal Services (University of Sydney, Australia). Animals were supplied 
water and standard mouse chow Gordon Rat and Mouse Pellets (Yandeera, 
Australalia) ad libitum. Compressed paper bedding was obtained from Fibrecycle Pty 
Ltd (Mudgeeraba, Australia). Animal studies were carried out according to a protocol 
approved by the Animal Ethics Committee of the University of Sydney (protocol 
number 5457) and complied with the Australian code of practice for the care and use 
of animals for scientific purposes. 
 
Each mouse weighed, on average, 24 g initially. Animals were randomly allocated to 
each treatment group and were allowed about a week to adapt to the environment 
prior to the commencement of experimentation. 
 
Initially, hundred mice were allocated to five different treatment groups, each group 
consisting of twenty mice. Mice in each group were ear-tagged with identification 
numbers for future weighing and monitoring purposes. Each group of mice was 
housed in an individual opaque plastic box with wired tops, compressed paper 
pellets for bedding and a red translucent plastic igloo. The climate for the animals 
was maintained at a temperature of 24 (±1) °C with a photoperiod cycle of 12 hours 
provided by yellow fluorescent lamps, without any UVR emission. Dry-pelleted 
commercial feed was provided to the mice and the tap water was provided through 
the gravity-feed bottle. Feed, water and bedding were regularly changed by 
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Laboratory animal services (LAS) staff of the University of Sydney. Mice were 
regularly monitored and weighed once a week for 36 weeks. This is shown in Figure 
2.5 and Figure 2.6. 
v NOTE: 1 mouse from group 1 (vehicle group) died in week 4 for unknown 
reasons, leaving a total of 99 mice for in vivo studies. 
 
Figure 2.5 Average weight of mice 
 
0	
5	
10	
15	
20	
25	
30	
35	
0	 2	 4	 6	 8	 10	 12	 14	 16	 18	 20	 22	 24	 26	 28	 30	 32	 34	 36	
Av
er
ag
e	
w
ei
gh
t	(
g)
	
Weeks	
Vehicle	
1,25(OH)2D3	11.4	pmol/cm2	20(OH)D3	11.4	pmol/cm2	20(OH)D3	22.8	pmol/cm2	20(OH)D3	114	pmol/cm2	
 65 
 
Figure 2.6 Average weight of mice at different time points 
For the purpose of comparison between groups, 4 different time points (9th, 18th, 27th 
and 36th week) were selected to show average weight of each treatment group. . 
Data presented as mean ± SEM. Each treatment group results significantly different 
to each other group at each time point is expressed as: * p<0.05, otherwise p = NS. 
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2.3.2 EXPERIMENTAL DESIGN 
Animals were divided into treatment groups of five for a photocarcinogenesis study. 
The test substances were, vehicle, 1,25(OH)2D3 (11.4 ρmol/cm2), 20(OH)D3 (11.4 
ρmol/cm2), 20(OH)D3 (22.8 ρmol/cm2) and 20(OH)D3 (114 ρmol/cm2) . 
 
2.3.3 UV SOURCE AND IRRADIATION 
The solar simulated UVR source was one fluorescent UVB tube flanked by six UVA 
tubes. The output of these lamps is shown in Figure 2.5. Before commencing 
irradiation, UV lamps were warmed up for about 20 minutes. Then the broadband 
measurement was taken using a calibrated broadband radiometer to estimate the 
output of UVR. The highest measurement along different parts of the lamps was 
used to calculate the time period for a dose of 1 MED using the following formula: 
Time of exposure (1 MED) = 25.43 / UVB output. 
 
Whilst the UV lamps were being warmed up, mice in each group were transferred 
from their original boxes into the perforated boxes, in order to permit enough airflow 
during UV irradiation. At the same time, a sticker with identification details for each 
box was put onto the perforated boxes respectively. Then a film of cellulose 
triacetate filter was put on to each box in order to eliminate UVR of wavelengths 
below 290 nm. Then the boxes were directly exposed to UVR source and were 
irradiated for a time period, depending on the UVR output each day. On average, 
mice were all exposed to about 15 minutes of UVR. A cooling fan was turned on 
during irradiation to assist ventilation for the mice.  
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Figure 2.7 Output of UV lamps used in animal studies 
Output of solar simulated UVR measured in May, 2013. 
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2.3.4 TOPICAL TREATMENTS 
Mice were treated topically on the dorsum (Figure 2.6) with the following treatments 
immediately after UV irradiation: vehicle only, 1,25(OH)2D3 (11.4 ρmol/cm2), 
20(OH)D3 (11.4 ρmol/cm2), 20(OH)D3 (22.8 ρmol/cm2) and 20(OH)D3 (114 ρmol/cm2) 
. 
 
Figure 2.8 Application of topical treatments 
Treatments were applied to the dorsum of mice using a pipette. 
 
The mice were treated with 100 µL of treatments immediately after each irradiation. 
Topical treatment involved pipetting the treatments from vials and gently applying 
them on the dorsum of the skin of each mouse, covering approximately 7 cm2 
(Figure 2.6). Applied lotions were left on cages to air-dry prior to returning them to 
their home boxes. Topical treatments consisted of a base lotion containing the test 
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compound. The stock solutions of 1,25(OH)2D3 and 20(OH)D3 were dissolved in a 
spectroscopic ethanol and diluted in the base lotion consisting of ethanol, propylene 
glycol and water to a final solvent ratio of 2:1:1 respectively. 
 
2.3.5 PHOTOCARCINOGENESIS 
Groups of 20 mice were exposed to a suberythemal dose of UVR on five days per 
week for 10 weeks. The daily dose provided 0.658 kJ/m2 UVB and 20.30 kJ/m2 UVA, 
which is approximately one minimal erythemal dose (MED) for these mice. 
Immediately after irradiation mice were treated topically on the irradiated dorsal skin 
with 100 microlitres of either vehicle only, 1,25(OH)2D3 (11.4 ρmol/cm2), 20(OH)D3 
(11.4 ρmol/cm2), 20(OH)D3 (22.8 ρmol/cm2) or 20(OH)D3 (114 ρmol/cm2). Mice 
receiving 1,25(OH)2D3 (11.4 ρmol/cm2) showed non-significant weight reductions 
compared with mice in other treatment groups. This was likely to be due to 
dehydration caused by hypercalcemia/hypercalciuria. Hypercalcemia results in 
increased urinary calcium, which then causes a diuresis and subsequent weight 
loss. Calcium levels were not directly measured but mice were monitored for weight 
loss as it is a sensitive sign of hypercalcemia. Weight loss was not observed in mice 
treated with either vehicle group or 20(OH)D3 group. In order to improve dehydration 
in 1,25(OH)2D3 group, sipper bottles were replaced with bigger holes to facilitate 
drinking. Following this change, no significant weight loss was observed - average 
mouse weight did not differ significantly from that of other groups (Figure 2.6). 
 
The time of appearance, type of tumour (whether papilloma, cyst, hematoma or 
SCC) and the location of tumours were mapped for each mouse over the next 30 
weeks. Skin tumour formation was confirmed by a tumour outgrowth of 1 mm or 
greater in diameter, which was expressed as the tumour incidence, the average 
tumour multiplicity (average number of tumours per tumour-bearing mouse), tumour 
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latency, and tumour regressions for each treatment group. SCCs were assessed 
visually by experienced researchers (Nicole Painter and Vivien Reeve) and then 
confirmed histologically.  
 
2.3.6 IMMUNOSUPPRESSION STUDIES 
The contact hypersensitivity response was tested to investigate the effects of 
1,25(OH)2D3 and 20(OH)D3 on UVR-induced systemic immunosuppression. Mice 
were sensitised approximately one week after the photocarcinogenesis study 
finished, with 100 µL of 2% oxazolone (Sigma, St. Louis, MO, USA) (w/v) in absolute 
alcohol, applied to the non-irradiated abdominal skin. A group of age-matched, non 
UV-irradiated mice were used as a control. Sensitisation was repeated on the 
subsequent day with the same treatment to ensure sensitisation in all areas of 
abdominal skin. The sensitised mice were challenged one week after by application 
of 5 µL 2% oxazolone to each surface of the pinnae of both ears so that each mouse 
received 20 µL in total. Ear thickness measurements were recorded to estimate the 
amount of oedema before challenge and at the designated time points (18 and 20 
hours) after challenge. 
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2.3.7 SKIN BIOPSIES AND TUMOUR COLLECTION 
Mice with SCCs greater than 1 cm in diameter were euthanized by CO2 asphyxiation 
and the skin sample was harvested with scissors and forceps. The collected sample 
was stored in formalin for future histological analyses and record. 
 
2.3.8 STATISTICAL ANALYSIS 
For mass monitoring of mice, results are expressed as mean ± 1 SEM. Comparisons 
between treatment groups were made by one-way analysis of variance (ANOVA) 
followed by Tukey’s multiple comparison test using the GraphPad InStat statistical 
program (GraphPad Software Inc., San Diego, CA). 
 
For in vivo studies, results are based on 19-20 mice per group for the 
photocarcinogenesis study and 11 mice in age matched control group. Results are 
expressed as mean ± 1 standard deviation (SD) or ± 1 SEM as indicated. 
Comparisons between treatment groups were made by one-way analysis of variance 
(ANOVA) followed by Dunnett’s multiple comparisons test using the GraphPad 
InStat statistical program (GraphPad Software Inc., San Diego, CA). 
 
The Mantel-Haenszel log rank test (Mantel and Haenszel 1959) was used to analyze 
incidence data in the photocarcinogenesis study. Using this test, all treatments were 
compared to vehicle-treated group over the entire time course of the experiment, 
specifically by testing whether there was a difference in the risk of developing a 
tumour. 
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3 RESULTS 
3.1 IN VITRO STUDIES WITH HACAT CELLS AND 
KERATINOCYTES 
3.1.1 CELL VIABILITY AFTER UVR AND TREATMENT WITH 20(OH)D3 AND 
1,25(OH)2D3  
Treatment of HaCaT cells or keratinocytes with 20(OH)D3 or 1,25(OH)2D3, immediately after 
UVR for incubation period of 24 hours did not show significant photoprotection, as 
determined by an increase cell viability after UVR (Figure 3.1; p = NS). 
 
Figure 3.1 Cell viability after UVR 
Viability of HaCaT cells and keratinocytes after UV exposure and various treatments was 
expressed as a percentage of sham-irradiated group. Results are expressed as mean ± SD. 
n = 4 replicates per group. 
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3.2 IN VIVO STUDIES 
3.2.1 PHOTOCARCINOGENESIS 
Figure 3.2 shows representative photographs of the papillomas and squamous cell 
carcinomas (SCC), which developed in mice subjected to the photocarcinogenesis protocol, 
while Figure 3.3 shows photomicrographs of tumour histology. 
 
Figure 3.2 Papilloma and SCCs 
Photographs of papilloma (A) and SCCs (B and C) are taken from different mice. 
Photograph B shows the SCC of mouse that was sacrificed at 35 weeks and C shows SCC 
of mouse at 40 weeks. Note the difference in shapes of SCCs between B and C; B is an 
elevated above the most superficial skin layer and contains a “crater”, whilst C is more 
flattened. This is usually suggestive of the difference in degree of cancer cell invasion into 
deeper layers of skin. 
A 
1.3 mm 
7.2 mm 
C 
10 mm 
B
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Figure 3.3 Photomicrographs of papilloma and SCCs 
a) Papilloma showing epidermal hyperplasia with no significant dermal invasion (10x). 
b) “Horn pearls” typically seen in SCC, keratinisation on tumour surface and within 
abnormal cells in the epidermis. A lump of cells of epidermal origin invading into 
dermis (pale mauve colour) is typical characteristic feature of SCC (10x). 
c) SCC showing extensive keratinisation (10x). 
Scale bar = 400 µm 
  
C 
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3.2.1.1 INCIDENCE 
Tumour incidence was calculated as the per cent of mice in each group bearing one or more 
tumours, recorded on a weekly basis throughout the 40 week in vivo study. Table 3.1 shows 
statistical data generated by a Mantel-Cox log rank analysis of incidence data (GraphPad, 
Prism) in which all treatments were compared to vehicle group over the entire time course of 
the experiment, specifically by testing whether there was a difference in the risk of 
developing a tumour. Treatment with 1,25(OH)2D3 (11.4 ρmol/cm2) resulted in a significantly 
lowered risk of tumour development compared with vehicle treatment. However, treatment 
with the CYP11A1 metabolite, 20(OH)D3 (11.4 and 22.8 ρmol/cm2) resulted in a significantly 
higher risk of developing a tumour compared with vehicle treatment. Figure 3.4 clearly 
demonstrates the reduction in tumour incidence over the 40 week time course by 
1,25(OH)2D3 (11.4 ρmol/cm2). Figure 3.5 (A-D) shows individual group “survival” by using 
Kaplan-Meier method as a comparison between each group and the vehicle group in relation 
to the percentage of mice bearing tumour across 40 weeks.  
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Figure 3.4 Tumour incidence 
Tumour incidence, including both papillomas and SCCs. Incidence calculated at each 
weekly time point as per cent of mice in each group bearing at least one tumour. In all 
groups except the 1,25(OH)2D3 group, the tumour incidence reached 100% by the end of the 
40 week study. 
 
Table 3-1 Summary of Mantel-Cox log rank analysis of papilloma incidence 
data 
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Figure 3.5 Survival analysis of tumour incidence 
In conventional survival analysis, y-axis is expressed as percentage deaths. For this 
analysis, survival curves show time until each mouse present any tumour (papillomas and/or 
SCCs), expressed as a percentage of total number of mice at specific time point. Note that 
in the 1,25(OH)2D3-treated group (A), mice developed tumours more gradually over 40 
weeks, whereas all mice in vehicle group presented tumours by week 30. In all other groups 
treated with 20(OH)D3, mice developed more tumours at earlier time points similar to the 
vehicle-treated group. In the 1,25(OH)2D3-treated group, the tumour incidence did not reach 
100% at the end of the study. 
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3.2.1.2 MULTIPLICITY 
Tumour multiplicity was calculated as the average number of tumours per tumour-
bearing mouse. Figure 3.6 shows the average tumour multiplicity throughout the 40 
week course of study. Significant reductions in tumour multiplicity were observed 
with 1,25(OH)2D3 (11.4 ρmol/cm2). Average tumour multiplicity was significantly 
reduced from 1.43 ± 0.18 in vehicle-treated mice to 0.00 ± 0.00 (p < 0.001) in mice 
treated with 1,25(OH)2D3 (11.4 ρmol/cm2) at 20 weeks following the first UVR 
exposure, and remained significantly reduced for the entire study thereafter. At week 
30, a further reduction in multiplicity was noted in the 1,25(OH)2D3-treated group, 
from 7.61 ± 0.94 in the vehicle group to 2.82 ± 0.44 (p < 0.001) and an increase in 
multiplicity was noted in 20(OH)D3-treated group (22.8 pmol/cm2), 13.17 ± 1.23 (p < 
0.01). Tumour multiplicity at three time points is shown in Figure 3.7. Statistical 
information was obtained by one-way ANOVA followed by Dunnett’s multiple 
comparisons test. 
 
  
B 
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Figure 3.6 Tumour multiplicity 
Average tumour multiplicity, including both papillomas and SCCs. Multiplicity 
calculated at each weekly time point as the average number of tumours per tumour-
bearing mouse. 
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Figure 3.7 Tumour multiplicity; 10 weeks interval 
Average tumour multiplicity at 20, 30 and 40 weeks for each treatment group. Data 
presented as mean ± SEM. Each treatment group results significantly different to 
vehicle group at each time point is expressed as: ** p<0.01, *** p<0.001.  
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3.2.1.3 LATENCY 
Latency is the period to onset of first tumour (or papilloma) formation in mice and this 
varied between the treatment groups. As shown in Figure 3.8, the average latency in 
the vehicle-treated group was 20.8 ± 2.8 weeks from the first UVR exposure and 
topical treatment. This was similar to 1,25(OH)2D3-treated mice (11.4 ρmol/cm2) 
which had an average latency of 20.8 ± 6.9 weeks. On the other hand, all three 
20(OH)D3 groups had significantly lower average latency compared to the vehicle-
treated group. The average latency for the three doses of 20(OH)D3 from the lowest 
to highest were 17.9 ± 3.1 (p<0.01) , 16.9 ± 3.4 (p<0.001) and 17.9 ± 3.3 (p<0.01) 
weeks respectively, all significantly lower in comparison to the vehicle-treated group. 
Statistical information was obtained by one-way ANOVA followed by Dunnett’s 
multiple comparisons test. 
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Figure 3.8 Tumour latency 
Average tumour latency, calculated as mean time period from first UVR exposure to 
first tumour outgrowth. Significantly different from vehicle: ** P < 0.01, *** P<0.001, n 
= 20, (except vehicle n =19), mean ± SD. 
 
**	
***	
**	
0	 5	 10	 15	 20	 25	 30	 35	 40	
Vehicle 
1,25(OH)2D3 
11.4 ρmol/
cm2 
20(OH)D3 
11.4 ρmol/
cm2 
20(OH)D3 
22.8 ρmol/
cm2 
20(OH)D3 
114 ρmol/
cm2 
Average latency to first tumour 
 84 
3.2.1.4 REGRESSIONS 
A regression was recorded when a previously noted tumour totally disappeared. In 
the vehicle group there was a total of 76 tumour regressions; 47% of tumours 
completely regressed. There was a total of 55 regressions in 1,25(OH)2D3 11.4 
ρmol/cm2 group, and percentage of tumour regressions in this group was 79%. It 
should be noted that there were fewer tumours overall in this 1,25(OH)2D3-treated 
group. Table 3.2 shows the regression data for each treatment group.  
 
Table 3-2 Tumour regression data 
 
Treatment group No. regressions Total no. of tumours 
at 40 weeks. 
Regression 
incidence 
Vehicle 76 162 47% 
1,25(OH)2D3 11.4 
ρmol/cm2 
55 70 79% 
20(OH)D3 11.4 ρmol/cm2 92 228 40% 
20(OH)D3 22.8 ρmol/cm2 112 237 47% 
20(OH)D3 114 ρmol/cm2 114 146 78% 
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3.2.1.5 SQUAMOUS CELL CARCINOMAS (SCCS) 
Some of the papillomas progressed to squamous cell carcinomas (SCCs) throughout 
the course of the study. This was later confirmed histologically by extensive invasion 
into the dermis (as shown in figure 3.3). Table 3.3 shows statistical data generated 
by a Mantel-Cox log rank analysis of incidence data in which all treatments were 
compared to control over the entire time course of the experiment, specifically by 
testing whether there was a difference in the risk of SCC development.  
  
Table 3-3 Summary of SCC incidence data 
 
 Table 3-4 Summary of Mantel-cox log rank analysis of SCC incidence 
data 
 
* The log rank analysis between the vehicle and the 1,25(OH)2D3 treatment groups 
showed that mice in the 1,25(OH)2D3 group were at significantly lower risk of 
developing a SCC than those in the vehicle treatment group. 
Treatment group No. of mice with SCC No. SCCs SCC Incidence 
Vehicle 8 9 42% 
1,25(OH)2D3 11.4 ρmol/cm2 3 4 15% 
20(OH)D3 11.4 ρmol/cm2 9 9 45% 
20(OH)D3 22.8 ρmol/cm2 10 11 50% 
20(OH)D3 114 ρmol/cm2 6 9 30% 
Comparison by Mantel-cox Log Rank Analysis P value Significantly lower 
Vehicle Vs. 1,25(OH)2D3 11.4 ρmol/cm2 0.041 * yes 
Vehicle Vs. 20(OH)D3 11.4 ρmol/cm2 0.711 no 
Vehicle Vs. 20(OH)D3 22.8 ρmol/cm2 0.358 no 
Vehicle Vs. 20(OH)D3 114 ρmol/cm2 0.616 no 
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Figure 3.9 Percentage SCC incidence at 40 weeks 
Mice that received 1,25(OH)2D3 treatment showed significantly less risk of 
developing SCC (refer to table 3.4). 
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3.2.1.6 IMMUNOSUPPRESSION 
Neither 1,25(OH)2D3 nor 20(OH)D3 were effective at inhibiting UVR-induced 
immunosuppression measured by the contact hypersensitivity reaction at the end of 
the 40 week photocarcinogenesis study. Figure 3.10 shows the average change in 
ear thickness for non-irradiated age matched mice and UV-irradiated mice treated 
with vehicle, 1,25(OH)2D3 or 20(OH)D3. Average change in ear thickness was 
calculated as the difference between pre- and post-challenge ear thickness. Note 
that the mice in this study were all UV-irradiated as they were involved in the 
photocarcinogenesis study except for the mice in the age-matched control (AMC) 
group and all had reduced ear swelling in comparison to the age-matched control 
group (p<0.0001). 
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Figure 3.10 Average change in ear thickness 18 hours post-challenge 
*AMC refers to Age-matched control mice. n = 11 for AMC, n = 12 for vehicle, n = 16 
for 1,25(OH)2D3 11.4 ρmol/cm2, n = 15 for 20(OH)D3 11.4 ρmol/cm2, n = 13 for 
20(OH)D3 22.8 ρmol/cm2 and n = 14 for 20(OH)D3 114 ρmol/cm2 group, mean ±SD. 
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Table 3-5 Comparison of ear swelling against age-matched control 
group 
 
 
 
Comparison by GraphPad prism analysis P value 
AMC Vs. Vehicle <0.0001 *** 
AMC Vs. 1,25(OH)2D3 11.4 ρmol/cm2 <0.0001 *** 
Vehicle Vs. 20(OH)D3 11.4 ρmol/cm2 <0.0001 *** 
Vehicle Vs. 20(OH)D3 22.8 ρmol/cm2 <0.0001 *** 
Vehicle Vs. 20(OH)D3 114 ρmol/cm2 <0.0001 *** 
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3.3 DISCUSSION 
The results from short term in vitro studies showed that 20(OH)D3 was not 
photoprotective in HaCaT cells. Neither 20(OH)D3 nor 1,25(OH)2D3 were found to be 
protective against UV-induced cell death in primary keratinocytes either as examined 
by a cell viability assay. This protection against acute UV damage in primary 
keratinocytes is in contrast with what my colleagues (Tongkao-on et al., 2015) found; 
20(OH)D3 and 1,25(OH)2D3 reduced UVR-induced DNA damage in primary 
keratinocytes and hence are photoprotective (Tongkao-on et al., 2015). Since 
photoprotection was not observed in my studies in primary keratinocytes, it is not 
possible to interpret the results in HaCaT cells. One possible reason that it was 
predicted that HaCaT cells would not be a good model for keratinocytes for this 
functionality is that there could be differences between HaCaT cells and normal 
keratinocytes that could affect the vitamin D non-genomic pathway or other 
intracellular mechanisms indirectly associated with photoprotection such as 
apoptosis. HaCaT cells express the vitamin D receptor (VDR) at equal levels to 
keratinocytes, which is essential for genomic actions of vitamin D compounds, but 
whether these cells express ERp57, the other protein required for photoprotection 
(Sequeira et al, 2012) is unknown. Furthermore, recent findings revealed that UVB 
increases apoptosis and autophagy-related genes such as bcl2, caspase 3 and LC3 
in HaCaT cells at the same time (Ryu et al., 2011). In addition, it was found that 
HaCaT cells have different transcriptional profiles of cornified-envelope associated 
genes such as filaggrin, loricin and involucrin to normal human keratinocytes (Seo et 
al, 2012). These proteins may only play a minor role in photoprotection but the 
difference in the level of expression of these proteins suggests a limitation of HaCaT 
cells as a model to study UVR-induced damage. Furthermore, previous studies 
conducted by the Mason group showed that 1,25(OH)2D3 significantly increases the 
expression of p53 protein in keratinocytes after UVR exposure, which plays an 
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important role in photoprotection (Gupta et al., 2007). However, photoprotection by 
1,25(OH)2D3 in HaCaT cells is likely to be limited as they have p53 mutation.  
 
The reasons for the lack of demonstrated photoprotection by 1,25(OH)2D3 in 
keratinocytes in this study are unclear. The most likely reason is inexperience of the 
experimenter, since this positive finding has been observed by numerous other 
researchers in the lab and by other groups (Dixon et al., 2012; Haes et al, 2003). 
Dixon et al (2012) reported that 1,25(OH)2D3 reduced UVR-induced cell loss 
significantly in keratinocytes in comparison to vehicle group. Also keratinocytes are 
derived from different donors and do vary on this basis in terms of how susceptible 
they are to photodamage and how much they are protected by a given concentration 
of 1,25(OH)2D3 (Gupta et al., 2007). 
 
The results from our photocarcinogenesis study reinforced the findings in previous 
studies by the Mason group that demonstrated the photoprotective ability of 
1,25(OH)2D3 against acute UVR-induced events, such as DNA damage, which is 
associated with an initiation of carcinogenesis (Dixon et al., 2011). For the long term 
in vivo photocarcinogenesis study, novel data, outlined in this thesis, one dose of 
1,25(OH)2D3 and three different doses of 20(OH)D3 were tested. The single dose of 
1,25(OH)2D3 was used as a positive control, as it had been shown in previous 
studies by my group to inhibit photocarcinogenesis in these mice (Dixon et al., 
2011). In my study, mice that received 1,25(OH)2D3 (11.4 ρmol/cm2) showed 
markedly reduced tumour multiplicity and significantly lower incidence of SCCs. 
These results confirmed that 1,25(OH)2D3 at 11.4 ρmol/cm2 was very effective at 
reducing UVR-induced skin carcinogenesis and was aligned with the previous study. 
These results also provided a good positive control for the other test agent. On the 
other hand, in spite of predictions made from the studies of my colleagues (Tongkao-
on et al., 2015), 20(OH)D3 was found not to be protective against UV-induced 
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carcinogenesis in female Skh:hr1 mice at any of three doses – 11.4, 22.8 and 114 
ρmol/cm2. Instead, the three doses, in general, showed significantly lower average 
tumour latency and higher average tumour multiplicity compared to the vehicle-
treated group. More specifically, the lower doses of 20(OH)D3 – 11.4 and 22.8 
ρmol/cm2, showed significantly increased risk of tumour incidence. Also, 20(OH)D3 
at 22.8 ρmol/cm2 showed significantly increased average tumour multiplicity at 30 
weeks against the vehicle-treated group (Figure 3.7), and the lowest average tumour 
latency, compared to other doses of 20(OH)D3 (Figure 3.8). In contrast, 20(OH)D3 at 
114 ρmol/cm2 did not confer significantly increased risk of developing tumours (Table 
3-1), and showed the lowest SCC incidence amongst other doses. Although the 
results are inconclusive, it can be proposed from the parameters explored in this in 
vivo study that 20(OH)D3 at 22.8 ρmol/cm2 provides the least protection from UV-
induced carcinogenesis whilst the highest dose of 114 ρmol/cm2 showed the most 
protection amongst other doses. These results suggest the need for future 
investigation into various doses of 20(OH)D3 in delivering protective effects against 
carcinogenesis. This is possible with 20(OH)D3 as it does not cause hypercalcaemia 
in mice at a dose as high as 30 !"/!" , whilst 1,25(OH)2D3 causes severe 
hypercalcaemia at a dose of 2 !"/!" , thereby suggesting that 20(OH)D3 can 
potentially have greater therapeutic window (Wang et al., 2012). 
 
Thus the results did not support the use of 20(OH)D3 as photoprotective agent since 
it was not shown to be effective in reducing tumour incidence, multiplicity or 
progression of premalignant lesions to squamous cell carcinomas (SCCs). This is in 
stark contrast to the previous results, using acute UV exposure, from our colleagues 
(Tongkao-on., 2015), who found that there were significant reductions in UVR-
induced DNA damage such as thymine dimers in human keratinocytes (by 
approximately 70%) and in male and female Skh:hr1 mice (by 98%) at both 23 and 
46 ρmol/cm2 doses of 20(OH)D3. My colleagues also conducted a contact 
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hypersensitivity (CHS) study on both 20(OH)D3 and 1,25(OH)2D3 in these mice, and 
found that they provided protection to UV-induced immunosuppression in female 
hairless mice, but not in male hairless mice. The photocarcinogenesis studies 
involved only female mice because fighting amongst male mice cause skin lesions, 
which may interfere with a long term photocarcinogenesis study. In their studies, the 
ear swelling in female hairless mice decreased in the vehicle-treated group following 
UVR. On the other hand, in 1,25(OH)2D3 and 20(OH)D3 treated groups, the immune 
response following UVR measured as increase in ear swelling, was close to that of 
non-irradiated treated mice, suggesting immune protection. 
 
Previous CHS studies from colleagues (Wannit Tongkao-on, personal 
communication) have shown that the 1,25(OH)2D3-treated group showed significantly 
less immune suppression following the 40 week photocarcinogenesis study. 
Although from our CHS study, 1,25(OH)2D3 was not shown to be immune protective 
at 40 weeks , there could be several reasons why this maybe the case. First, since 
the CHS experiment was conducted after the completion of 40 weeks of 
carcinogenesis study, the number of mice in each group varied due to animal ethics 
requirements (mice were culled when tumours reached 1 cm), reducing the n value. 
Secondly, as these mice were tagged for identification using ear tags that had been 
in place for 40 weeks, the majority of mice had one side of their ears with tags 
already swollen, preventing accurate measurement. Although both ears were 
measured in this study, it may be necessary to exclude ears with tags from the 
measurement for future studies. 
 
The conflicting evidence for 20(OH)D3 between the early studies by colleagues 
(Tongkao-on et al., 2015) that showed protection against acute effects of UV 
exposure, and its inefficacy in our long term skin carcinogenesis study suggest that a 
clear relationship between its acute and long term effects does not exist or at least 
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that other factors may play a role in UV-induced tumour formation. Other factors may 
include the ability to stimulate the growth of blood vessels, ability to stimulate local 
invasion and metastasis, and the ability to regulate proteins involved in tumour 
growth. Recent study about the effect of 1,25(OH)2D3 on E-cadherin expression 
showed that it increases the expression of E-cadherin in breast cancer cells, thereby 
decreasing the aggressiveness of cancerous cells (Lopes et al., 2012). It could be 
worthwhile to investigate the effects of 20(OH)D3 on proteins involved in cell-cell 
adhesion and hence cancer invasion. Also, 20(OH)D3 may play a role in formation of 
tumour vasculature. Formation of tumour vasculature is regulated by the balance of 
anti-angiogenic and pro-angiogenic molecules. However, recent report revealed that 
1,25(OH)2D3, mediated by VDR, has antiproliferative actions on tumour-derived 
endothelial cells (Chung et al., 2009). Examination of blood vessels in tumours from 
the mice given different treatments was not within the scope of this study, but could 
be undertaken in the future.  
 
All in all, it can be concluded that reduction in photocarcinogenesis may not be 
adequately determined just by the ability to reduce DNA damage or 
immunosuppression from acute UV exposure.  
 
It is interesting to note that QW (1α-hydroxymethyl-16-ene-24,24-difluoro-25-
hydroxy-26,27-bis-homovitaminD3 or QW-1624F2-2), another analogue of 
1,25(OH)2D3 showed a similar pattern of protection against UV exposure as 
20(OH)D3. The results in Dixon et al (2012) showed that QW significantly (p < 0.05–
0.01) reduced UV-induced DNA lesions (CPD) in skin fibroblasts and keratinocytes 
and reduced cell death after UV exposure. Also, in the mouse model, they found that 
QW (22.8 ρmol/ cm2) reduced immunosuppression in a short term UV exposure 
model. Yet these results did not translate well into the photocarcinogenesis study. In 
the photocarcinogenesis study, which followed the same protocol as was used in our 
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study, the same dose of QW that reduced UV-induced immunosuppression, did not 
reduce tumour incidence nor did it reduce tumour multiplicity. In fact, the average 
tumour multiplicity measurement of QW was similar to that of the vehicle-treated 
group and was significantly higher than that of the 1,25(OH)2D3-treated group, 
suggesting that QW was not photoprotective in a chronic UV exposure experiment, 
at least at the concentration that was used (Dixon et al., 2012). Thus the results of 
our in vivo study using 20(OH)D3 paralleled the recent studies on QW, suggesting 
that vitamin D-like compounds may have different mechanisms in response to acute 
or chronic exposures to UVR. 
 
Albino hairless mice are reliable model of carcinogenesis for a number of reasons. 
Firstly, being hairless, these mice do not need to be shaved and thus artefacts due 
to skin damage from shaving could be avoided. Their lack of tyrosinase activity 
results in reduced production of melanin pigment in the skin and retina (Reeve and 
Ley, 2004; Saran et al., 2004), leading to acceleration in tumour development and 
thus a convenient method for induction and analysis of carcinogenesis. In such 
accelerated models of skin cancer, results may be more informative with respect to 
the protective capacity of vitamin D compounds. It has been proposed that inbred 
mouse strains differ in their susceptibility to the promotional and malignant 
conversion stages of carcinogenesis (Brown and Balmain, 1995), but it is also 
arguable that the use of inbred mice for carcinogenesis studies is advantageous due 
to the reduced genetic variability between treatment groups, allowing for more 
meaningful comparisons. In addition, species-specific differences in immune cell 
populations of skin in mice and humans pose problems in interpreting results from 
cellular immune reactions. As mentioned earlier, mouse skin has a prominent 
population of Vγ5+ dendritic epidermal T cells (DETCs) that secrete pro-
inflammatory cytokines. However, this cell population is absent in human skin and 
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can thus be a limitation in mouse model to study mechanisms that drive 
inflammation in human skin upon exposure to UVR (Pasparakis et al., 2014).  
 
To conclude, there are numerous limitations to be considered about this study. 
Firstly, for in vitro experiments, cell viability assay conducted for the investigation of 
photoprotection of keratinocytes provided only superficial data. Other experiments to 
investigate the barometer of cellular damage such as caspase assay for apoptosis 
could be done in the future. Western blots for proteins involved in DNA repair such 
as XPC and OGG1 were conducted but the results were not shown due to technical 
difficulties. Secondly, the limitations of in vivo study involve investigating 
immunosuppression using the same mice previously used for the 
photocarcinogenesis study. These mice had ear tags on one ear since the beginning 
of in vivo experiment, and this may have affected tests on the other ear by the time 
of immunosuppression studies. For future studies, tail marking may eliminate this 
concern. 
 
Aside from the effects of compounds, UVR and other experimental environments 
mentioned above, it has been suggested through a recent study that difference in 
experimenter’s gender could induce different physiological stress in mice and rats. A 
study has found that male-related olfactory stimuli induce a robust physiological 
stress response that results in stress-induced analgesia (Sorge et al, 2014). This 
suggests that male handling can interfere with correct representation of immune 
response in mice. As both a male and a female engaged in this photocarcinogenesis 
study, there is a possibility that male handling could have caused immune 
suppression in mice and hence misrepresentation of the effects of vitamin D 
compounds on immune response. In addition, the fact that painting of treatments 
was done by inexperienced experimenter further compromises the effects of 
compounds in all degrees. 
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Nevertheless, it is reasonable to conclude overall that while 20(OH)D3 protects 
against acute UV damage, it is not protective, long term, for photocarcinogenesis. 
The reasons for this discrepancy are unclear. The implications for the importance of 
the CYP11A1 pathway in photoprotection are also not clear, since there are many 
other metabolites of vitamin D and overirradiation products which are produced by 
this enzyme in skin (Tuckey at el., 2008). 
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4 CONCLUSION AND FUTURE DIRECTIONS 
In conclusion, neither 1,25(OH)2D3 nor 20(OH)D3 were photoprotective in primary 
keratinocytes in the short term in vitro studies, presented here, although both 
compounds reduced DNA damage and improved keratinocyte viability in studies 
undertaken by other members of the Mason group. 
 
Despite the photoprotective effects of 20(OH)D3 in the short term preliminary studies 
(Tongkao-on et al., 2015), 20(OH)D3 was not protective in long term in vivo 
carcinogenesis. Only 1,25(OH)2D3 was found to be photoprotective in the long term 
in vivo studies. The fact that the short term photoprotective effects of 20(OH)D3 did 
not translate into long term photocarcinogenesis protection suggests a number of 
things. It is possible that 20(OH)D3 may have effects to reduce cell apoptosis or it 
may enhance angiogenesis in early tumours. Although none of these were tested, it 
would be possible to examine blood vessel formation in the micrographs of the 
papillomas and SCCs. These methods could include the Verhoeff-Van Gieson stain 
for vasculature, Ki-67 stain for lymphocyte invasion, caspase assay or TUNEL for 
apoptosis, and LC3-II immunoblot for autophagy. As previously mentioned in chapter 
1, photocarcinogenesis is a multistage, multistep process. Thus, in the future, it 
could be worthwhile investigating the effects of 20(OH)D3 not only when the tumour 
is fully developed but examining the tumours at different time points. For future 
studies, it would be worthwhile to investigate the difference in the expression levels 
of specific proteins such as XPC and p53, after treatment with both compounds, as 
these are crucial in protection against UVR. 
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Much attention has focused on UVB-induced DNA damage such as pyrimidine 
dimers but not much on reactive oxygen species (ROS). Although UVB is thought to 
be the main culprit of photocarcinogenesis, effects of UVA on skin cannot be 
neglected. The effects of UVA on photocarcinogenesis have been controversial but it 
is known to cause DNA damage indirectly by inducing ROS and lipid peroxidation 
(Nishigori, 2005). Future studies could examine whether 20(OH)D3 reduces oxidative 
damage to DNA or lipids. 
 
As described in chapter 1, there are two distinct pathways of action for vitamin D 
compounds; a classical/genomic pathway and a rapid-acting/non-genomic pathway. 
It is known that 20(OH)D3 is a partial agonist of VDR but pathways mediating the 
actions of this compound remain uncertain. A recent study has reported that 
20(OH)D3 is capable of activating non-genomic pathway. The study revealed that 
20(OH)D3 and 20,23(OH)2D3, act as antagonists of RORα and RORγ mediated 
transactivation. RORα and RORγ are nuclear receptors involved in global and local 
homeostasis. They are expressed in major skin cell populations including epithelial 
cells of the epidermis, hair follicles, sebaceous glands, sweat glands, dermal 
fibroblasts and immune cells. The fact that 20(OH)D3 can act as antagonists on 
immune cells expressing these nuclear receptors suggests the possibility of 
20(OH)D3 acting as a regulator of local or systemic immune response via RORα and 
RORγ receptors (Slominski et al., 2014). Even more recently, in the Mason group, it 
has been demonstrated that the reduction in UV-induced thymine dimers by 
20(OH)D3 requires both the classical vitamin D receptor and the protein ERp57 
(Jeremy Han, personal communication). ERp57 has been shown by Sequeira et al 
(2012) to co-immunoprecipitate with the vitamin D receptor and to be essential for 
the photoprotective effects of 1,25(OH)2D3. 
 
 100 
In chapter 1, it was mentioned that the knockout of 1α-hydroxylase enzyme 
(CYP27B1), enzyme essential for the production of 1,25(OH)2D3, does not increase 
the susceptibility to photocarcinogenesis (Teichert et al., 2011). For this reason, 
20(OH)D3, a vitamin D metabolite by CYP11A1 enzyme in the skin, was 
investigated. Thus, it could be interesting to examine the effects of the knock out of 
CYP11A1 enzyme in mouse skin, if these mice could be bred. Recently, a 
genetically modified mouse with a potential LoxP site flanking the CYP11A1 site has 
been generated by the Sanger Institute in the UK. 
 
CYP11A1 (cytochrome P450scc) is an enzyme that catalyzes the conversion of 
cholesterol into progenolone, the first and rate-limiting step of steroidogenesis. It is 
expressed in the gonads and the adrenals under the control of pituitary peptide 
hormones. Knock out of CYP11A1 gene could result in pseudohermaphroditism. In 
order to avoid any side effects, tissue-specific factors would be necessary. This is 
possible in conditional gene knockout method using the Cre-lox system. With a 
keratin-14 promoter for Cre-, an epidermis-specific knockout of CYP11A1 gene is 
possible, allowing us to explore the physiological effects of other metabolites of 
CYP11A1 cleavage other than 20(OH)D3 (Scharfenberger et al., 2014). Although, 
20(OH)D3 is the major metabolite of CYP11A1 induced metabolism of vitamin D3, 
there are also other metabolites such as 20,23(OH)2D3, 20,22(OH)2D3, 17,20(OH)2D3 
and 17,20,23(OH)3D3. Of these metabolites, 20,23(OH)2D3 has shown to inhibit 
proliferation of keratinocytes, and its inhibitory effect on DNA synthesis was shown 
to be comparable to that of 1,25(OH)2D3 and 20(OH)D3, suggesting a potential role 
in anti-carcinogenic activity (Slominski et al., 2014; Janjetovic et al., 2010). 
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